Document:

EX-10.1

 Exhibit 10.1 

CONFIDENTIAL 

EXECUTION VERSION 

AMENDED AND RESTATED EXCLUSIVE (EQUITY) AGREEMENT 

This Amended and Restated Exclusive (Equity) Agreement (“Agreement”) between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
(“Stanford”), an institution of higher education having powers under the laws of the State of California, and LogicBio Therapeutics, Inc. (“LogicBio”), a corporation having a principal place of business at 700 Main Street,
Cambridge, MA 02139, is effective on the 31st day of January, 2018 (“Amendment Date”). 
  

	1.	 BACKGROUND 

Stanford has an assignment of an invention of a technology to insert a gene or genes of interest without disrupting the target gene. It is co-owned with the University of Texas and entitled “Using Homologous Recombination to Create Genetically Engineered Cells for Cell and Gene Based Therapy,” was invented in the laboratories of Professor
Matthew Porteus and Professor Mark Kay, and is described in Stanford Docket S11-451 (“Gene Insertion Technology”). The Gene Insertion Technology was made in the course of research supported by the
Carter Foundation. Stanford will only be licensing its rights in this jointly owned Gene Insertion Technology to LogicBio. 
 Stanford has another
assignment of a related invention that is a method for site-specific gene targeting that does not require nucleases. It is entitled “Gene Targeting Without Nucleases,” was invented in the laboratory of Professor Mark Kay, and is described
in Stanford Docket S14-131 (“Gene Targeting Technology”, and collectively with the Gene Insertion Technology, the “Gene Technology” or “GT”). The Gene Targeting Technology was
made in the course of research supported by the National Institutes of Health. 
 Stanford has an assignment of three inventions of novel AAV vectors with
new and improved properties. They are entitled “Novel AAV capsids with new transduction and nonimmune properties”, which includes LK03, described in Stanford Docket S06-098, “Chimeric AAV
Capsids for High Efficiency Nucleic Acid Transfer,” described in Stanford Docket S11-298, and “Novel AAV Capsid, NP-59,” described in Stanford Docket S15-305 (collectively, “Vector Technology” or “VT”). The Vector Technology was invented in the laboratory of Professor Mark Kay and made in the course of research supported by the National
Institutes of Health. 
 Stanford wants to have the Gene Technology and the Vector Technology perfected and marketed as soon as possible so that resulting
products may be available for public use and benefit. 
 Stanford and LogicBio entered into the Exclusive (Equity) Agreement, dated as of December 18,
2015 (the “Prior Agreement,” and such date, the “Effective Date”), pursuant to which Stanford granted LogicBio a license under the Gene Technology and Vector Technology, subject to the terms of the Prior Agreement. 

  
 PAGE 1
OF 30 
 [***] PORTIONS OF THIS EXHIBIT HAVE
BEEN REDACTED PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION
OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 EXECUTION VERSION 

 

 Stanford and LogicBio wish to amend the Prior Agreement to revise the scope of the licenses granted
thereunder and certain of the diligence requirements and financial terms set forth therein, as set forth in this Agreement. 
 Stanford and LogicBio hereby
agree to amend and restate the Prior Agreement as follows: 
  

	2.	 DEFINITIONS 

  

	2.1	 “Active Indication” has the meaning set forth in Section 6.2.

  

	2.2	 “Biological Material” means
(a) pAAV-DJ and pHelper vectors, (b) NP59 Capsid and (c) LK03 Capsid, in each case provided by Stanford to LogicBio under this Agreement. 

 

	2.3	 “Capsid Patent” means (A) with respect to NP59 Capsid, Stanford’s U.S. Patent
Application, Serial Number 15/435212 filed February 16, 2017, and PCT application PCT/US2017/18226 and (B) with respect to LK03 Capsid, Stanford’s U.S. Patent Application, Serial Number 13/594,773 filed August 24th, 2012 and PCT application PCT/US2012/052400, and in each case ((A)-(B)), any domestic or foreign patent application corresponding thereto, and any divisional, continuation, substitution, or
reexamination application, extension, and each patent that issues or reissues from any of these patent applications. Any claim of an unexpired Capsid Patent is presumed to be valid unless it has been held to be invalid by a final judgment of a court
of competent jurisdiction from which no appeal can be or is taken. The Capsid Patent excludes any continuation-in-part patent application or patent.

  

	2.4	 “Capsid Selection Notice” has the meaning set forth in Section 3.4.

  

	2.5	 “Capsid Selection Notice Date” means the earlier of (A) the date on which Stanford
receives the Capsid Selection Notice and (B) [***] months following the Amendment Date. 

  

	2.6	 “Change of Control” means the following, as applied only to the entirety of that
part of LogicBio’s business that exercises all of the rights granted under this Agreement: 

  

	 	(A)	 acquisition of ownership—directly or indirectly, beneficially or of record—by any non-affiliate third person or group (within the meaning of the U.S. Securities Exchange Act of 1934 and the rules of the SEC or equivalent body under a different jurisdiction) of the capital stock of LogicBio
representing more than 45% of either the aggregate ordinary voting power or the aggregate equity value represented by the issued and outstanding capital stock of LogicBio; and/or 

 

	 	(B)	 the sale to any non-affiliate third party of all or substantially all
LogicBio’s assets and/or business in one transaction or in a series of related transactions. 

  
 PAGE 2
OF 29 
 [***] PORTIONS OF THIS EXHIBIT HAVE
BEEN REDACTED PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION
OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 EXECUTION VERSION 

 

	2.7	 “Classical Gene Therapy” means an AAV vector containing a payload consisting of an exogenous
promoter-transgene-poly A for episomal expression. 

  

	2.8	 “Covered Product” means a product or part of a product, the making, using, importing or
selling of which, absent this license, infringes, induces infringement, or contributes to infringement of one or more Valid Claim(s) within a Licensed Patent. 

 

	2.9	 “Exclusive” means that, subject to Section 3.5 and 3.6 and Article 5,
Stanford will not grant further licenses under the GT Licensed Patents in the Therapeutics Field of Use or the Tissue Field of Use in the Licensed Territory. 

  

	2.10	 “Fully Diluted Basis” means the total number of shares of LogicBio’s issued
and outstanding common stock, assuming: 

  

	 	(A)	 the conversion of all issued and outstanding securities convertible into common stock; 

 

	 	(B)	 the exercise of all issued and outstanding warrants or options, regardless of whether then exercisable; and

  

	 	(C)	 the issuance, grant, and exercise of all securities reserved for issuance pursuant to any LogicBio stock or
stock option plan then in effect. 

  

	2.11	 “GT Licensed Patent(s)” means Stanford’s Patent Applications listed in
Appendix A and any domestic or foreign patent application corresponding thereto, and any divisional, continuation, substitution, or reexamination application, extension, and each patent that issues or reissues from any of these patent applications.
Any claim of an unexpired GT Licensed Patent is presumed to be valid unless it has been held to be invalid by a final judgment of a court of competent jurisdiction from which no appeal can be or is taken. Neither party will file a continuation-in-part to a GT Licensed Patent. 

  

	2.12	 “Licensed Capsid” means (A) prior to the Capsid Selection Notice Date, NP59 Capsid and
LK03 Capsid, and (B) following the Capsid Selection Notice Date, the Selected Capsid. 

  

	2.13	 “Licensed Capsid Product” means a Licensed Product or part thereof, the making, using,
importing or selling of which, absent this license, infringes, induces infringement, or contributes to infringement of one or more Valid Claim(s) within a Capsid Patent with respect to a Licensed Capsid. 

 

	2.14	 “Licensed Field of Use” means the Therapeutics Field of Use, the Tissue Field of
Use and the Non-Exclusive Field of Use. 

  

	2.15	 “Licensed Patent(s)” means the GT Licensed Patent and VT Licensed Patent.

  

	2.16	 “Licensed Product” means Covered Product and Material Product. For clarity,
Licensed Products include Licensed Capsid Products. 

  
 PAGE 3
OF 29 
 [***] PORTIONS OF THIS EXHIBIT HAVE
BEEN REDACTED PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION
OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 EXECUTION VERSION 

 

	2.17	 “Licensed Territory” means the world. 

 

	2.18	 “LK03 Capsid” means the LK03 capsid described in PCT/US2012/52400 and U.S. Patent
No. 9,169,299. 

  

	2.19	 “Material Product” means a product or part of a product which (i) is not a Covered
Product, and (ii) made using or containing Biological Material. 

  

	2.20	 “Net Sales” means all gross revenue derived by LogicBio or sublicensees,
from the sale, transfer or other disposition of Licensed Product to any third party, whether or not such third party is an end user. Net Sales excludes the following items (but only as they pertain to the making, using, importing or selling of
Licensed Products, are included in gross revenue, and are separately accounted for): 

  

	 	(A)	 import, export, excise and sales taxes, and custom duties; 

 

	 	(B)	 costs of insurance, packing, and transportation from the place of manufacture to the customer’s premises
or point of installation; 

  

	 	(C)	 costs of installation at the place of use; 

 

	 	(D)	 credit for returns, allowances, or trades; and 

 

	 	(E)	 amounts received for any Licensed Product used in research and/or development or clinical trials provided at
cost or as free samples for promotional use. 

 For clarity, in the event that there is any sale of Licensed Products
between LogicBio and its distributor or contract sales organization for resale, Net Sales shall be calculated only based on the sale between LogicBio and its distributor or contract sales organization, as applicable, provided that LogicBio does not
derive additional income from the resale of Licensed Products by such distributor or contract sales organization, as applicable. For clarity, such arrangements with distributors or contract sales organizations shall not be considered Sublicenses.

  

	2.21	 “Nominated Tissues” has the meaning set forth in Section 3.3.

  

	2.22	 “Non-Exclusive Field of Use” means human
therapeutics to treat hemophilia A and Alpha-1 antitrypsin disease, with the exception that treatment of hemophilia A using “Classical Gene Therapy” is not included in the Non-Exclusive Field of Use.

  

	2.23	 “Nonroyalty Sublicensing Consideration” means any consideration attributable to
the (i) GT Licensed Patents or (ii) VT Licensed Patents sublicensed in the [***] Field of Use, in each case received by LogicBio from a sublicensee hereunder for a Sublicense but excluding any consideration for: 

 

	 	(A)	 royalties on Net Sales for Licensed Products (royalties on Net Sales of Licensed Products by sublicensees will
be treated as if LogicBio made the sale of such product); 

  
 PAGE 4
OF 29 
 [***] PORTIONS OF THIS EXHIBIT HAVE
BEEN REDACTED PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION
OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 EXECUTION VERSION 

 

	 	(B)	 investments in LogicBio stock; 

 

	 	(C)	 research and development expenses calculated on a fully burdened basis; 

 

	 	(D)	 debt; 

  

	 	(E)	 reimbursement of out-of-pocket
patent prosecution and maintenance expenses for Patent Matters; and 

  

	 	(F)	 the sale of substantially all of the business or assets of LogicBio (or its assignee) whether by merger, sale
of stock or assets or otherwise. 

  

	2.24	 “NP59 Capsid” means the NP-59
capsid as described in the invention titled “Novel AAV Capsid, NP-59,” Stanford Docket S15-305. 

 

	2.25	 “Patent Matters” means preparing, filing, and prosecuting broad and extensive
patent claims (including any interference or reexamination actions) for Stanford’s benefit in the Licensed Territory and for maintaining all GT Licensed Patents and VT Licensed Patents. 

 

	2.26	 “[***] Field of Use” means the diagnosis, prevention or treatment of [***] in
humans. 

  

	2.27	 “Selected Capsid” has the meaning set forth in Section 3.4. 

 

	2.28	 “Stanford Indemnitees” means Stanford, Stanford Health Care, Lucile Packard
Children’s Hospital at Stanford, and their respective trustees, officers, employees, students, agents, faculty, representatives, and volunteers. 

  

	2.29	 “Sublicense” means any agreement between LogicBio and a third party that
contains a grant to Stanford’s Licensed Patents regardless of the name given to the agreement by the parties; however, an agreement to make, have made, use or sell Licensed Products on behalf of LogicBio is not considered a Sublicense.

  

	2.30	 “Technology” means the information and materials listed in Appendix E and provided by Stanford
to LogicBio under this Agreement, and any Biological Material. Technology may or may not be confidential in nature. 

  

	2.31	 “Therapeutics Field of Use” means human therapeutics to treat methylmalonic
acidemia (MMA), propionic acidemia, HIV, influenza, malaria, Crigler Najjar Syndrome, Tyrosinemia Type I, Wilson’s disease, hemophilia B, and Glycogen Storage Disease 1 and Glycogen Storage Disease 3.  

 

	2.32	 “Tissue Field of Use” means 

 

	 	(A)	 prior to the [***] anniversary of the Amendment Date: 

 

	 	(1)	 the diagnosis, prevention or treatment of human disease via genome editing without a nuclease.

  

	 	(B)	 following the [***] anniversary of the Amendment Date and until the [***] anniversary thereof:

  
 PAGE 5
OF 29 
 [***] PORTIONS OF THIS EXHIBIT HAVE
BEEN REDACTED PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION
OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 EXECUTION VERSION 

 

	 	(1)	 the diagnosis, prevention or treatment of any human disease of liver tissue that affects less than 200,000
persons in the United States as of the first anniversary of the Amendment Date via genome editing without a nuclease; and 

  

	 	(2)	 the diagnosis, prevention or treatment of human disease of the Nominated Tissues via genome editing without a
nuclease. 

  

	 	(C)	 following the [***] anniversary of the Amendment Date: 

 

	 	(1)	 the prevention, treatment or diagnosis of Active Indications via genome editing without a nuclease.

  

	2.33	 “VT Licensed Patent(s)” means Stanford’s U.S. Patent Applications, Serial Number listed
in Appendix B and any domestic or foreign patent application corresponding, and any divisional, continuation, substitution, or reexamination application, extension, and each patent that issues or reissues from any of these patent applications. Any
claim of an unexpired VT Licensed Patent is presumed to be valid unless it has been held to be invalid by a final judgment of a court of competent jurisdiction from which no appeal can be or is taken. “VT Licensed Patent(s)” exclude any continuation-in-part applications, which Stanford does not plan to file. For clarity, VT Licensed Patents include Capsid Patents with respect to the Licensed Capsids.

  

	2.34	 “Valid Claim” shall mean a claim of (i) any issued, unexpired patent within the GT
Licensed Patents and VT Licensed Patents which has not been dedicated to the public, disclaimed, abandoned or held invalid or unenforceable by a court or other government agency of competent jurisdiction in a decision from which no appeal can be
taken or is otherwise not taken, or (ii) a pending patent application within the GT Licensed Patents and VT Licensed Patents which has not been irrevocably cancelled, withdrawn or abandoned, provided if a claim of pending patent application has
not issued as a claim of an issued patent within [***] years after the filing date from which such claim takes priority, such pending claim shall not be a Valid Claim for purposes of this Agreement. 

 

	3.	 GRANT 

  

	3.1	 Licensed Patents Grant. Subject to the terms and conditions of this Agreement, Stanford grants LogicBio
a license under the Licensed Patents in the Licensed Field of Use, to make, have made, use, import, offer to sell and sell Licensed Products in the Licensed Territory. 

 

	 	(A)	 GT Licensed Patents. 

 

	 	(1)	 The license is Exclusive for the GT Licensed Patents in the Therapeutics Field of Use and the Tissue Field of
Use, including the right to sublicense under Article 4, until the expiration of the last Valid Claim included in the GT Licensed Patents. 

  
 PAGE 6
OF 29 
 [***] PORTIONS OF THIS EXHIBIT HAVE
BEEN REDACTED PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION
OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 EXECUTION VERSION 

 

	 	(2)	 The license is non-exclusive for the GT Licensed Patents in the Non-Exclusive Field of Use until the expiration of the last Valid Claim included in the GT Licensed Patents. 

  

	 	(B)	 VT Licensed Patents.  

 

	 	(1)	 The license is non-exclusive for the VT Licensed Patents in the
Licensed Field of Use until the expiration of the last Valid Claim included in the VT Licensed Patents. 

  

	 	(2)	 Notwithstanding the foregoing, the license is Exclusive for the Capsid Patents with respect to the Licensed
Capsids in the [***] Field of Use until the expiration of the last Valid Claim included in such Capsid Patents. 

  

	3.2	 Technology Grant. Subject to the terms and conditions of this Agreement, Stanford grants LogicBio a non-exclusive license for Technology to make, have made, use, import, copy, perform, display, distribute, and transmit Technology in the Licensed Field of Use. 

 

	3.3	 Nomination of Tissues. At any time prior to the [***] anniversary of the Amendment Date, LogicBio
may provide to Stanford a written notice listing up to [***] human tissues that will be the subject of LogicBio’s development efforts with respect to the technology licensed under this Agreement. By way of example, and without
limiting the foregoing, for purposes of this Agreement “human tissue” includes skeletal muscle tissue, lung tissue and the central nervous system. Beginning on the date on which LogicBio provides such written notice to Stanford, such
tissues shall be deemed “Nominated Tissues”; provided that if LogicBio does not incur at least $[***] in research and development expenses with respect to the application of GT and VT to a Nominated Tissue in the [***] month period
beginning on the [***] anniversary of the Amendment Date or any anniversary of the Amendment Date thereafter, then such tissue will no longer be deemed a “Nominated Tissue” following the end of such [***] month period.

  

	3.4	 Capsid Selection. At any time prior to [***] months following the Amendment Date, LogicBio shall provide
to Stanford a written notice (the “Capsid Selection Notice”) listing one of either the NP59 Capsid or the LK03 Capsid (such listed capsid, the “Selected Capsid”) that will be the subject of LogicBio’s future development
efforts with respect to the technology licensed under this Agreement. The Capsid Selection Notice shall include a summary of the LogicBio research results with respect to LogicBio’s selection of the Selected Capsid. Following the Capsid
Selection Notice Date, the Exclusive license under the VT Licensed Patents in the [***] Field of Use set forth in Section 3.1(B)(2) shall only apply with respect to the Selected Capsid. 

 

	3.5	 Retained Rights. Stanford retains the right, on behalf of itself, Stanford Health Care, Lucile Packard
Children’s Hospital at Stanford, and all other non-profit research institutions, to practice the Licensed Patent for any non-profit purpose, including sponsored
research and collaborations. LogicBio agrees that, notwithstanding any other provision of this Agreement, it has no right to enforce the Licensed Patent against any such institution. Stanford and any such other institution have the right to publish
any information included in a Licensed Patent. 

  
 PAGE 7
OF 29 
 [***] PORTIONS OF THIS EXHIBIT HAVE
BEEN REDACTED PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION
OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 EXECUTION VERSION 

 

	3.6	 Specific Exclusion. Stanford does not: 

 

	 	(A)	 grant to LogicBio any other licenses, implied or otherwise, to any patents or other rights of Stanford other
than those rights granted under Licensed Patent, regardless of whether the patents or other rights are dominant or subordinate to any Licensed Patent, or are required to exploit any Licensed Patent or Technology; 

 

	 	(B)	 commit to LogicBio to bring suit against third parties for infringement, except as described in Article 14; and

  

	 	(C)	 agree to furnish to LogicBio any technology or technological information other than the Technology or to
provide LogicBio with any assistance. 

  

	3.7	 Third Party Field of Use. The parties understand that Stanford has granted or will grant to one third
party a license under the GT Licensed Patents prior to the Effective Date for autologous ex vivo use for non-episomal DNA delivery and maintenance (a) with that third party’s proprietary system,
and (b) for hematopoietic stem cells for sickle cell or beta thallasemia (the “Third Party Field of Use”). For clarity, the Licensed Field of Use specifically excludes the Third Party Field of Use. 

 

	4.	 SUBLICENSING 

  

	4.1	 Permitted Sublicensing. If, at the time of the Sublicense grant, LogicBio is developing or selling at
least one Licensed Product directly or through its affiliates or sublicensees, LogicBio may grant Sublicenses: 

  

	 	(1)	 to the GT Licensed Patents in the Licensed Field of Use; 

 

	 	(2)	 to the VT Licensed Patents in the [***] Field of Use; and 

 

	 	(3)	 to the VT Licensed Patents and Technology only in conjunction with the GT Licensed Patents in the Therapeutics
Field of Use and/or Tissue Field of Use. 

 Sublicenses with any exclusivity must include diligence requirements
commensurate with the diligence requirements of Appendix C. Stanford agrees that LogicBio may apportion without discrimination between LogicBio owned or controlled technology and Stanford patents a commercially reasonable percentage of sublicensing
payments made to Stanford pursuant to Section 4.7, including, for clarity, where LogicBio sublicenses Stanford patents together with such other technology, provided however that LogicBio provides Stanford with the proposed apportionment and
justification prior to LogicBio’s payment pursuant to Section 8.1. Stanford and LogicBio agree to meet to discuss such proposed apportionment if in Stanford’s opinion the apportionment does not reasonably reflect the value of the
Licensed Patents. 

  
 PAGE 8
OF 29 
 [***] PORTIONS OF THIS EXHIBIT HAVE
BEEN REDACTED PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION
OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 EXECUTION VERSION 

 

	4.2	 Required Sublicensing. If LogicBio is unable or unwilling to serve or develop a potential market or
market territory for which there is a reputable company with adequate resource, and a bona fide, detailed proposal to develop a Licensed Product covered by the GT Licensed Patent in the Therapeutics Field of Use for such potential market or
territory that would not interfere with any existing or future Licensed Products of LogicBio, as reasonably demonstrated by LogicBio in a written document to Stanford, who is willing to be a sublicensee, LogicBio will, at Stanford’s request,
negotiate in good faith a Sublicense with any such company. Stanford would like licensees to address unmet needs, such as those of neglected patient populations or geographic areas, giving particular attention to improved therapeutics, diagnostics
and agricultural technologies for the developing world. 

  

	4.3	 Sublicense Requirements. Any Sublicense: 

 

	 	(A)	 is subject to this Agreement, except that the financial terms may differ; 

 

	 	(B)	 will reflect that any sublicensee will not further sublicense, unless Stanford and LogicBio agree in writing;

  

	 	(C)	 will prohibit sublicensee from paying royalties to an escrow or other similar account; 

 

	 	(D)	 will expressly include the provisions of Articles 8, 9, and 10 for the benefit of Stanford; and

  

	 	(E)	 will include the provisions of Section 4.4 and require the transfer of all the sublicensee’s
obligations to LogicBio, including the payment of royalties specified in the Sublicense (up to the earned royalty rates set forth in this Agreement), to Stanford or its designee, if this Agreement is terminated. If the sublicensee is a spin-out from LogicBio, LogicBio must guarantee the sublicensee’s performance with respect to the payment of Stanford’s share of Sublicense royalties if this Agreement is terminated. 

 

	4.4	 Litigation by Sublicensee. Any Sublicense must include the following clauses: 

 

	 	(A)	 In the event sublicensee brings an action seeking to invalidate any Licensed Patent: 

 

	 	(1)	 sublicensee will double the payment paid to LogicBio during the pendency of such action. Moreover, should the
outcome of such action determine that any claim of a patent challenged by the sublicensee is both valid and infringed by a Licensed Product, sublicensee will pay triple times the payment paid under the original Sublicense; 

 

	 	(2)	 sublicensee will have no right to recoup any royalties paid before or during the period challenge;

  

	 	(3)	 any dispute regarding the validity of any Licensed Patent shall be litigated in the courts located in Santa
Clara County, and the parties agree not to challenge personal jurisdiction in that forum; and 

  
 PAGE 9
OF 29 
 [***] PORTIONS OF THIS EXHIBIT HAVE
BEEN REDACTED PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION
OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 EXECUTION VERSION 

 

	 	(4)	 sublicensee shall not pay royalties into any escrow or other similar account. 

 

	 	(B)	 Sublicensee will provide written notice to Stanford at least three months prior to bringing an action seeking
to invalidate a Licensed Patent. Sublicensee will include with such written notice an identification of all prior art it believes invalidates any claim of the Licensed Patent. 

 

	4.5	 Copy of Sublicenses and Sublicensee Royalty Reports. LogicBio will submit to Stanford a copy of each
Sublicense, any subsequent amendments and all copies of sublicensees’ royalty reports. Beginning with the first Sublicense, the Chief Financial Officer or equivalent will certify annually regarding the name and number of sublicensees.

  

	4.6	 Sharing of Sublicensing Income. LogicBio will pay to Stanford a portion of all Nonroyalty Sublicensing
Consideration for the Sublicense of any Licensed Patents, which will be determined by the stage of the Licensed Product when the Sublicense is signed, as provided below: 

 

	 	(A)	 [***]% before an IND at the FDA; 

 

	 	(B)	 [***]% after an IND and before Phase IIB (or Phase II if there is no Phase IIA); 

 

	 	(C)	 [***]% after Phase IIB (or Phase II if there is no Phase IIA) and before Phase III; 

 

	 	(D)	 [***]% after Phase III and before an NDA; and 

 

	 	(E)	 [***]% after an NDA. 

For clarity, in each case for (A)-(E) above, clinical phases corresponding to those described in (A)-(E) above in an equivalent regulatory
agency outside of the U.S. shall also apply for determination of the stage of the Licensed Product. 
  

	4.7	 Royalty-Free Sublicenses. If LogicBio pays all royalties due Stanford from a sublicensee’s Net
Sales, LogicBio may grant that sublicensee a royalty-free or non-cash: 

  

	 	(A)	 Sublicense or 

  

	 	(B)	 cross-license. 

  

	5.	 GOVERNMENT RIGHTS 

This Agreement is subject to Title 35 Sections 200-204 of the United States Code. Among other things, these provisions
provide the United States Government with nonexclusive rights in the Licensed Patent. They also impose the obligation that Licensed Product sold or produced in the United States be “manufactured substantially in the United States.”
LogicBio will ensure all obligations of these provisions are met. 

  
 PAGE 10
OF 29 
 [***] PORTIONS OF THIS EXHIBIT HAVE
BEEN REDACTED PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION
OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 EXECUTION VERSION 

 

	6.	 DILIGENCE 

  

	6.1	 Milestones. Because the invention is not yet commercially viable as of the Effective Date, LogicBio will
use commercially reasonable efforts to develop, manufacture, and sell Licensed Product and will use commercially reasonable efforts to develop markets for Licensed Product. In addition, LogicBio will meet the milestones shown in Appendix C and
notify Stanford in writing as each milestone is met. LogicBio shall have the right to obtain one six (6) month extension to such milestone dates shown in Appendix C and the applicable diligence milestone date(s) and all subsequent milestone
dates shall be deemed extended; provided that LogicBio shall 1) make a written request providing reasonable justification for the needed extension; and 2) make a payment of $[***] for the extension at least 30 days prior to the date on which the
applicable milestone is due. In addition, in the event LogicBio anticipates the need to extend the timeframe for achievement of a milestone for reasons beyond the reasonable control of LogicBio, such as a delay due to a regulatory agency, LogicBio
will provide a written explanation of the reason therefor, and Stanford will consider in good faith granting an extension. 

  

	6.2	 Active Indications. Within 30 days following the [***] anniversary of the Amendment Date,
LogicBio will provide to Stanford a written notice listing all indications that relate to human liver tissue and the Nominated Tissues that are the subject of LogicBio’s research and development efforts with respect to the technology licensed
under this Agreement as of the third anniversary of the Amendment Date. Beginning on the third anniversary of the Amendment Date, such indications shall be deemed “Active Indications”; provided that, if LogicBio does not incur at least
$[***] in research and development expenses with respect to the application of GT and VT to an Active Indication in the [***] period beginning on the third anniversary of the Amendment Date or any [***] period thereafter, then such indication will
no longer be deemed an “Active Indication” following the end of such [***] period. 

  

	6.3	 Progress Report. By March 1 of each year, LogicBio will submit a written annual report to Stanford
covering the preceding calendar year. The report will include information sufficient to enable Stanford to satisfy reporting requirements of the U.S. Government and for Stanford to ascertain progress by LogicBio toward meeting this Agreement’s
diligence requirements (including without limitation LogicBio’s diligence obligations with respect to Nominated Tissues and Active Indications). Each report will describe, where relevant: (a) LogicBio’s progress toward
commercialization of Licensed Product, including work completed, key scientific discoveries, summary of work-in-progress, current schedule of anticipated events or
milestones, market plans for introduction of Licensed Product, (b) significant corporate transactions involving Licensed Product, (c) beginning with the first annual report following the first anniversary of the Amendment Date,
LogicBio’s research and development efforts with respect to each Nominated Tissue, and (d) beginning with the first annual report following the third anniversary of the Amendment Date, LogicBio’s research and development efforts with
respect to each Active Indication. LogicBio will specifically describe how each Licensed Product is related to each Licensed Patent. 

  

	6.4	 Clinical Trial Notice. LogicBio will notify the Stanford University Office of Technology Licensing prior
to commencing any clinical trials at Stanford. 

  
 PAGE 11
OF 29 
 [***] PORTIONS OF THIS EXHIBIT HAVE
BEEN REDACTED PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION
OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 EXECUTION VERSION 

 

	7.	 ROYALTIES 

  

	7.1	 Issue Royalty. LogicBio will pay to Stanford a noncreditable, nonrefundable license issue royalty of
$75,000 within [***] business days of the Effective Date. LogicBio will pay to Stanford a noncreditable, nonrefundable license issue royalty of $25,000 within [***] business days of the Amendment Date. 

 

	7.2	 Equity Interest. As further consideration, LogicBio will grant to Stanford 250,000 shares of common
stock in LogicBio. When issued, those shares will represent 4% of the stock in LogicBio on a Fully Diluted Basis. LogicBio agrees the shares are valued at $[***] per share and to provide Stanford with the capitalization table upon which the above
calculation is made. LogicBio will issue [***]% of all shares granted to Stanford pursuant to this Section 7.2 and Section 7.3 directly to and in the name of the inventors. Stanford will provide the name of the inventors and their
allocations within 3 months of the Effective Date. 

  

	7.3	 Anti-Dilution Protection. LogicBio will issue Stanford, without further consideration, any additional
shares of stock of the class issued pursuant to Section 7.2 necessary to ensure that the number of shares issued Stanford pursuant to Section 7.2 and this Section 7.3 does not represent less than 4% of the shares issued and
outstanding on a Fully-Diluted Basis at any time through the completion of issuance of all shares to be issued in connection with the First Round of bona fide equity investment in LogicBio from a single or group of investors which is both
(i) at least $3,999,900 in size and (ii) at a price per share which, when applied to stock actually outstanding immediately after such round, implies a post-financing equity valuation of LogicBio of at least $[***] (the “First Round
Financing”). Notwithstanding the foregoing, in the event the amount invested in the First Round Financing is greater than $3,999,900, the number of shares to be issued to Stanford shall be calculated as if the total amount invested in the First
Round Financing is $3,999,900 (the “Maximum Investment”). A “First Round” is a bona fide round of equity, warrant, option or convertible equity investment which includes all the tranches prior to the completion of the financing.
This right will expire upon the issuance of all shares to be issued in connection with such First Round, but will apply to all shares to be issued in or in connection with such First Round. 

 

	7.4	 Purchase Right.  

 

	 	(A)	 Stanford shall have the right, but not the obligation, to purchase for cash up to its Share of the securities
issued in any Qualifying Offering on the terms, and subject to the conditions, set forth in this Section 7.4 and Section 7.5 (the “Purchase Right”). For purposes of this Section 7.4 and Section 7.5:

  

	 	(1)	 “Adjustment Event” means the final closing of the first Threshold Qualifying Offering occurring after
the Effective Date. 

  

	 	(2)	 “Board of Directors” means (i) if LogicBio is organized as a corporation, its board of
directors, and (ii) if LogicBio is organized as a limited liability company, LogicBio manager(s) or member(s) or both that have the power to direct the principal management and activities of LogicBio, whether through ownership of voting
securities, by agreement, or otherwise. 

  
 PAGE 12
OF 29 
 [***] PORTIONS OF THIS EXHIBIT HAVE
BEEN REDACTED PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION
OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 EXECUTION VERSION 

 

	 	(3)	 “Qualifying Offering” means a private offering of LogicBio’s equity securities (or securities
convertible into or exercisable for LogicBio’s equity securities) for cash (or in satisfaction of debt issued for cash) having its final closing on or after the Effective Date and which includes investment by one or more venture capital,
professional angel, corporate or other similar institutional investors other than Stanford. For the avoidance of doubt, if LogicBio is a limited liability company, then “equity securities” means limited liability company interests in
LogicBio. 

  

	 	(4)	 “Share” means: 

 

	 	(i)	 [***]% with respect to any Qualifying Offering having a closing on or before the date of an Adjustment Event;
or 

  

	 	(ii)	 with respect to any Qualifying Offering having a closing after an Adjustment Event, but before a Termination
Event, the percentage necessary for Stanford to maintain its pro rata ownership interest in LogicBio on a Fully-Diluted Basis. 

  

	 	(5)	 “Threshold Qualifying Offering” means any Qualifying Offering which either (i) is at least
$[***] in size or (ii) involves the sale to outside investors of at least [***]% of the equity securities outstanding after such round on a Fully-Diluted Basis. 

 

	 	(6)	 The parties shall construe the term “Fully-Diluted Basis” mutatis mutandis in the case
where LogicBio is organized as a limited liability company. 

  

	 	(B)	 The Purchase Right shall terminate upon the earliest to occur of the following (each a “Termination
Event”): 

  

	 	(1)	 Stanford’s execution of an investor rights agreement or similar agreement (each a “Rights
Agreement”) in connection with a Threshold Qualifying Offering so long the Rights Agreement satisfies the terms of this Section 7.4 and Section 7.5 below; 

 

	 	(2)	 Stanford purchases less than its entire Share of a Qualifying Offering; 

 

	 	(3)	 Stanford fails to give an election notice within the Notice Period for a Qualifying Offering which has its
final closing within 90 days of the date such notice is received by Stanford and which is closed on terms that are the same or less favorable to the investors as the terms stated in LogicBio’s notice to Stanford; 

  
 PAGE 13
OF 29 
 [***] PORTIONS OF THIS EXHIBIT HAVE
BEEN REDACTED PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION
OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 EXECUTION VERSION 

 

	 	(4)	 The closing of a firm commitment underwritten public offering of LogicBio’s common stock; or

  

	 	(5)	 The closing of the sale of all or substantially all of LogicBio’s assets to a company publicly traded on
one of the major recognized exchanges. 

  

	 	(C)	 The Purchase Right shall not apply to the issuance of securities: (i) to employees, individuals who are
members of LogicBio’s Board of Directors as of the time of issuance, and service providers to LogicBio pursuant to a plan approved by LogicBio’s Board of Directors; or (ii) as additional consideration in lending or leasing
transactions; or (iii) to an entity pursuant to an arrangement that LogicBio’s Board of Directors determines in good faith is a strategic partnership or similar arrangement of LogicBio (i.e., an arrangement in which the entity’s
purchase of securities is not primarily for the purpose of financing LogicBio); or (iv) to owners of another entity in connection with the acquisition of that entity by LogicBio. 

 

	 	(D)	 For the avoidance of doubt: (i) any securities Stanford may acquire or have the right to acquire under
Section 7.2 or 7.3 shall not reduce the number of securities Stanford may purchase under this Section 7.4 or under any applicable Rights Agreement; and (ii) Stanford shall not be obligated to purchase under this Section 7.4 any
LogicBio securities it has the right to acquire under Section 7.2 or 7.3 above. 

  

	7.5	 Rights Agreements; Information Rights; Notice; Elections. 

 

	 	(A)	 LogicBio shall ensure that each Rights Agreement executed by Stanford in connection with a Qualifying Offering
will grant to Stanford the same rights as all other investors who are parties to that Rights Agreement. In particular, LogicBio shall ensure that each such Rights Agreement will grant to Stanford the same right to purchase additional securities in
future offerings, the same information rights, and the same registration rights as are granted to other parties thereto, including all such rights granted to any investor designated as a “Major Investor” or other similar designation, even
if Stanford is not so designated. 

  

	 	(B)	 Notwithstanding any terms to the contrary contained in any applicable Rights Agreement: 

 

	 	(1)	 Stanford shall not have any representation on the Board of Directors or rights to attend meetings of the Board
of Directors; 

  

	 	(2)	 In connection with all Qualifying Offerings, LogicBio shall give Stanford notice of the terms of the offering,
including: (i) the names of the investors, the allocation of equity securities among them and the total amounts to be invested by each of them in such offering; (ii) pre- and post- (projected)
financing capitalization table; (iii) investor presentation (if available); (iv) an introduction to the lead investor in such offering for the purpose of discussing the lead investor’s due diligence process; and (v) such other
documents and information as Stanford may reasonably request for the purpose of making an investment decision or verifying the amount of equity securities it is entitled to purchase in such offering; and 

  
 PAGE 14
OF 29 
 [***] PORTIONS OF THIS EXHIBIT HAVE
BEEN REDACTED PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION
OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 EXECUTION VERSION 

 

	 	(3)	 Stanford may elect to exercise its Purchase Right, in whole or in part, by notice given to LogicBio within
[***] Stanford business days (i.e., days other than Saturdays, Sundays, and holidays or other days on which Stanford is officially closed) after receipt of LogicBio’s notice (“Notice Period”). 

 

	 	(C)	 If Stanford has no information rights under a Rights Agreement and to the extent that such information has been
prepared by LogicBio for other purposes, so long as Stanford holds LogicBio securities, LogicBio shall furnish to Stanford, upon request and as promptly as reasonably practicable, LogicBio’s annual consolidated financial statements and annual
operating plan, including an annual report of the holders of LogicBio’s securities, and such other information as Stanford may reasonably request from time to time for the purpose of valuing its interest in LogicBio. 

 

	 	(D)	 Notwithstanding any notice provision in this Agreement to the contrary, any notice given under this Agreement
that refers or relates to any of Section 7.4 above or this Section 7.5 shall be copied concurrently to pvfnotices@stanford.edu; provided, however, that delivery of the copy will not by itself constitute notice for any purpose under this
Agreement. 

  

	7.6	 License Maintenance Fee. Beginning on the 1st
anniversary of the Effective Date and each anniversary of the Effective Date thereafter, LogicBio will pay Stanford a yearly license maintenance fee of: 

  

	 	(A)	 $[***] on the 1st and 2nd anniversaries; 

  

	 	(B)	 $[***] on the 3rd anniversary; 

 

	 	(C)	 $[***] on the 4th anniversary; 

 

	 	(D)	 $[***] on the 5th and 6th anniversaries; and 

  

	 	(E)	 $[***] on the 7th anniversary and each anniversary
thereafter. 

 Yearly maintenance payments are nonrefundable, but they are creditable each year as described in
Section 7.13. 
  

	7.7	 Milestone Payments. LogicBio will pay Stanford each of the following
one-time milestone payments: 

  

	 	(A)	 Due one time for the first Licensed Product to achieve the following milestones set forth in this
Section 7.7(A): 

  

	 	(1)	 $[***] for filing an IND with the FDA (or equivalent with another regulatory body); 

  
 PAGE 15
OF 29 
 [***] PORTIONS OF THIS EXHIBIT HAVE
BEEN REDACTED PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION
OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 EXECUTION VERSION 

 

	 	(2)	 $[***] upon dosing of the first patient; 

 

	 	(3)	 $[***] for dosing the first patient in a Phase II trial with the FDA (or equivalent with another regulatory
body); 

  

	 	(4)	 $[***] for dosing the first patient in a Phase III trial with the FDA (or equivalent with another regulatory
body); 

  

	 	(5)	 $[***] upon approval in the United States; and 

 

	 	(6)	 $[***] upon commercial launch of the Licensed Product. 

For clarity, the maximum due under this Section 7.7(A) is $[***]. 

 

	 	(B)	 Due one time for the second Licensed Product that achieves the following milestones set forth in this
Section 7.7(B): 

  

	 	(1)	 $[***] for filing an IND with the FDA (or equivalent with another regulatory body); 

 

	 	(2)	 $[***] for dosing the first patient in a Phase II trial with the FDA (or equivalent with another regulatory
body); 

  

	 	(3)	 $[***] for dosing the first patient in a Phase III trial with the FDA (or equivalent with another regulatory
body); 

  

	 	(4)	 $[***] upon approval in the United States; and 

 

	 	(5)	 $[***] upon commercial launch of the Licensed Product. 

 

	 	(C)	 Due one time for each subsequent Licensed Product in the Tissue Field of Use or [***] Field of Use or for
Licensed Capsid Products that achieve the following milestones set forth in this section 7.7(B): 

  

	 	(1)	 $[***] for filing an IND with the FDA (or equivalent with another regulatory body); 

 

	 	(2)	 $[***] for dosing the first patient in a Phase II trial with the FDA (or equivalent with another regulatory
body); 

  

	 	(3)	 $[***] for dosing the first patient in a Phase III trial with the FDA (or equivalent with another regulatory
body); 

  

	 	(4)	 $[***] upon approval in the United States; and 

 

	 	(5)	 $[***] upon commercial launch of the Licensed Product. 

  
 PAGE 16
OF 29 
 [***] PORTIONS OF THIS EXHIBIT HAVE
BEEN REDACTED PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION
OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 EXECUTION VERSION 

 

 It is further agreed and notwithstanding the above provisions of this Section 7.7, in
the event LogicBio receives a milestone payment from a sublicensee under a Sublicense and the milestone event giving rise to such milestone payment also triggers a payment obligation on the part of LogicBio under this Section 7.7, LogicBio
shall be obligated to pay Stanford only a single payment, such payment to be the higher of the applicable milestone payment set forth in this Section 7.7 and the payment owing to Stanford under Section 4.7 as applicable, with respect to
such milestone payment from such sublicensee. 
  

	7.8	 Earned Royalty. LogicBio will pay Stanford earned royalties on annual Net Sales as follows:

  

					
	 Annual Net Sales of Licensed Product
	  	Royalty Rate	 
	 < $[***]
	  	 	[***]	% 
	 > $[***], < $[***]
	  	 	[***]	% 
	 > $[***], < $[***]
	  	 	[***]	% 
	 > $[***], < $[***]
	  	 	[***]	% 
	 > $[***]
	  	 	[***]	% 

 Notwithstanding the above, the royalty rate for Licensed Products that are not Licensed Capsid Products sold
in the [***] Field of Use and that (i) are covered only by a Valid Claim of a VT Licensed Patent shall be [***]% of the applicable royalty rate set forth in this Section 7.8 above that would otherwise have been payable to Stanford for such
Licensed Products; and (ii) are Material Products only shall be [***]% of the applicable royalty rate set forth in this Section 7.8 above that would otherwise have been payable to Stanford for such Licensed Products. For clarity, if a
Licensed Capsid Product is sold both within and outside the [***] Field of Use, then the royalty step-downs set forth in the foregoing clauses (i) and (ii) shall apply to such Licensed Capsid Product, as applicable, solely to the extent such
Licensed Capsid Product is used or sold outside the [***] Field of Use. 
  

	7.9	 Earned Royalty if LogicBio Challenges the Patent. Notwithstanding the above, should LogicBio bring an
action seeking to invalidate any Licensed Patent, LogicBio will pay royalties to Stanford at the rate of [***]% of the Net Sales of all Licensed Products sold during the pendency of such action. Moreover, should the outcome of such action determine
that any claim of a patent challenged by LogicBio is both valid and infringed by a Licensed Product, LogicBio will pay royalties at the rate [***]% of the Net Sales of all Licensed Products sold. 

  
 PAGE 17
OF 29 
 [***] PORTIONS OF THIS EXHIBIT HAVE
BEEN REDACTED PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION
OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 EXECUTION VERSION 

 

	7.10	 Combination Product. In the event that a Licensed Product is sold in combination with another product,
component or service for which no royalty would be due hereunder if sold separately, Net Sales from such combination sales for purposes of calculating the amounts due under this Article 7 shall be calculated by multiplying the Net Sales of the
combination product or service by the fraction A/(A + B), where A is the average gross selling price during the preceding calendar quarter of the Licensed Product sold separately and B is the average gross selling price during the preceding calendar
quarter of the other product(s), component(s) or service(s). In the event that separate sales of the Licensed Product and/or of the other product(s), component(s) or service(s) were not made during the preceding calendar quarter, then the Net Sales
on the combination product shall be reasonably allocated between such Licensed Product, and such other product(s), component(s) or service(s) based upon their relative importance and proprietary protection as mutually agreed upon by Stanford and
LogicBio. 

  

	7.11	 Single Royalty. No more than one royalty payment under this Agreement shall be due to Stanford with
respect to a sale of a particular Licensed Product. Multiple royalties shall not be payable because any Licensed Product, or its manufacture, sale or use, is covered by more than one claim within the GT Licensed Patent and VT Licensed Patent. No
royalty shall be payable under Section 7.8 with respect to sales or other transfers of Licensed Products among LogicBio, its affiliates and sublicensees for resale (but the subsequent resale of such Licensed Product shall be included within the
computation of Net Sales). 

  

	7.12	 Royalty Stacking. If, during the term of this Agreement, LogicBio, its affiliates, or sublicensees makes
payments to for any technology or intellectual property rights necessary for the manufacturing and/or selling of a Licensed Product, [***]% of any payments made under such license(s) shall be deductible from any royalty payments due to Stanford;
provided that the amount of royalty payable to Stanford in any calendar year with respect to any such Licensed Product shall not be reduced under this Section 7.12, to less than[***]%. 

 

	7.13	 Creditable Payments. The license maintenance fee for a year may be offset against earned royalty
payments due on Net Sales occurring in that year. 

 For example: 

 

	 	(A)	 if LogicBio pays Stanford a $10 maintenance payment for year Y, and according to Section 7.8 $15 in earned
royalties are due Stanford for Net Sales in year Y, LogicBio will only need to pay Stanford an additional $5 for that year’s earned royalties. 

  

	 	(B)	 if LogicBio pays Stanford a $10 maintenance payment for year Y, and according to Section 7.8 $3 in earned
royalties are due Stanford for Net Sales in year Y, LogicBio will not need to pay Stanford any earned royalty payment for that year. LogicBio will not be able to offset the remaining $7 against a future year’s earned royalties.

  
 PAGE 18
OF 29 
 [***] PORTIONS OF THIS EXHIBIT HAVE
BEEN REDACTED PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION
OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 EXECUTION VERSION 

 

	7.14	 Obligation to Pay Royalties. During the term of this Agreement, an earned royalty is due Stanford under
this Agreement (i) on a country-by-country basis with respect to Net Sales of any Covered Product sold, used, manufactured or imported in an applicable country
until the expiration of the last Valid Claim within the Licensed Patents in such country covering such Licensed Product; and (ii) with respect to Net Sales of any Material Product for 10 years from the first commercial sale of any Licensed
Product. Commencing upon expiration of the applicable royalty term described in this Section 7.14 above, the licenses granted to LogicBio for the applicable Licensed Product will become perpetual, irrevocable, royalty-free and fully paid-up. Nonetheless, if certain Licensed Products are made, used, imported, or offered for sale before the date this Agreement terminates, and those Licensed Products are sold after the termination date, LogicBio
will pay Stanford an earned royalty for its exercise of rights based on the Net Sales of those Licensed Products. 

  

	7.15	 No Escrow. LogicBio shall not pay royalties into any escrow or other similar account.

  

	7.16	 Currency. LogicBio will calculate the royalty on sales in currencies other than U.S. Dollars using the
appropriate foreign exchange rate for the currency quoted by the Wall Street Journal on the close of business on the last banking day of each calendar quarter. LogicBio will make royalty payments to Stanford in U.S. Dollars. 

 

	7.17	 Non-U.S. Taxes. LogicBio will pay all non-U.S. taxes related to royalty payments. These payments are not deductible from any payments due to Stanford. 

  

	7.18	 Interest. Any payments not made when due will bear interest at the lower of (a) the Prime Rate
published in the Wall Street Journal plus [***] basis points or (b) the maximum rate permitted by law. 

  

	8.	 ROYALTY REPORTS, PAYMENTS, AND ACCOUNTING 

 

	8.1	 Quarterly Earned Royalty Payment and Report. Beginning with the first sale of a Licensed Product by
LogicBio, its affiliate, or a sublicensee or the first grant of a Sublicense, whichever is first, LogicBio will submit to Stanford a written report (even if there are no sales or Sublicenses) and an earned royalty payment and a Nonroyalty
Sublicensing Consideration payment (if applicable) within [***] days after the end of each calendar quarter. This report will be in the form of Appendix D and will state the number, description, and aggregate Net Sales of Licensed Product during the
completed calendar quarter and details about any Sublicenses. The report will include an overview of the process and documents relied upon to permit Stanford to understand how the earned royalties and Nonroyalty Sublicensing Consideration payment
are calculated. With each report LogicBio will include any earned royalty payment and Nonroyalty Sublicensing Consideration payment due Stanford for the completed calendar quarter (as calculated under Article 7 and Section 4.6).

  
 PAGE 19
OF 29 
 [***] PORTIONS OF THIS EXHIBIT HAVE
BEEN REDACTED PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION
OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 EXECUTION VERSION 

 

	8.2	 No Refund. In the event that a validity or non-infringement
challenge of a Licensed Patent brought by LogicBio is successful, LogicBio will have no right to recoup any royalties paid before or during the period challenge. 

 

	8.3	 Termination Report. LogicBio will pay to Stanford all applicable unpaid royalties accrued as of the date
of termination and submit to Stanford a written report within [***] days after the license terminates. LogicBio will continue to submit earned royalty payments and reports to Stanford after the license terminates, until all Licensed Products made or
imported under the license have been sold. 

  

	8.4	 Accounting. LogicBio will maintain records showing (a) LogicBio’s annual research and
development efforts with respect to the Nominated Tissues and Active Indications for three years following the end of the applicable year and (b) manufacture, importation, sale, and use of a Licensed Product for [***] years from the date of
sale of that Licensed Product. Records under the foregoing clause (b) will include general-ledger records showing cash receipts and expenses, and records that include: production records, customers, invoices, serial numbers, and related
information in sufficient detail to enable Stanford to determine the royalties payable under this Agreement. 

  

	8.5	 Audit by Stanford. Upon reasonable advance notice and during normal business hours LogicBio will allow
Stanford or its designee to examine LogicBio’s records kept in accordance with Section 8.4 to verify LogicBio’s diligence obligations with respect to the Nominated Tissues and Active Indications and payments made by LogicBio under
this Agreement. 

  

	8.6	 Paying for Audit. Stanford will pay for any audit done under Section 8.5. But if the audit reveals
an underreporting of earned royalties due Stanford of [***]% or more for the period being audited, LogicBio will pay the audit costs. 

  

	8.7	 Self-audit. LogicBio will conduct an independent audit of sales and royalties at least every 2 years if
annual sales of Licensed Product are over $[***]. The audit will address, at a minimum, the amount of gross sales by or on behalf of LogicBio during the audit period, the amount of funds owed to Stanford under this Agreement, and whether the amount
owed has been paid to Stanford and is reflected in the records of LogicBio. LogicBio will submit the auditor’s report promptly to Stanford upon completion. LogicBio will pay for the entire cost of the audit. 

 

	9.	 EXCLUSIONS AND NEGATION OF WARRANTIES 

 

	9.1	 Negation of Warranties. Stanford provides LogicBio the rights granted in this Agreement AS IS and WITH
ALL FAULTS. Stanford makes no representations and extends no warranties of any kind, either express or implied. Among other things, Stanford disclaims any express or implied warranty: 

 

	 	(A)	 of merchantability, of fitness for a particular purpose; 

 

	 	(B)	 of non-infringement; or 

  
 PAGE 20
OF 29 
 [***] PORTIONS OF THIS EXHIBIT HAVE
BEEN REDACTED PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION
OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 EXECUTION VERSION 

 

	 	(C)	 arising out of any course of dealing. 

 

	9.2	 No Representation of Licensed Patent. LogicBio also acknowledges that Stanford does not represent or
warrant: 

  

	 	(A)	 the validity or scope of any Licensed Patent; or 

 

	 	(B)	 that the exploitation of Licensed Patent will be successful. 

 

	10.	 INDEMNITY 

  

	10.1	 Indemnification. LogicBio will indemnify, hold harmless, and defend all Stanford Indemnitees against any
claim of any kind arising out of or related to the exercise of any rights granted LogicBio under this Agreement or the breach of this Agreement by LogicBio, provided that (i) Stanford promptly informs LogicBio in writing, in reasonable detail,
of any claim or threatened claim that may give rise to an obligation of indemnity under this Agreement of which Stanford becomes aware, and (ii) LogicBio shall have the first obligation to defend any such claim and the exclusive authority to
defend or settle any such claim or threatened claim provided that LogicBio must do so in a manner that does not adversely affect Stanford’s interests and it must obtain Stanford’s prior consent to any settlement. The indemnification
obligation of LogicBio under this Section 10.1 will not apply to any claim to the extent resulting from gross negligence or willful misconduct of a Stanford Indemnitee, or if the Stanford Indemnitee seeking indemnification makes any admission
regarding such claim without the prior written consent of LogicBio, which consent shall not be unreasonably withheld. 

  

	10.2	 No Indirect Liability. Neither party shall be liable for any special, consequential, lost profit,
expectation, punitive or other indirect damages in connection with any claim arising out of or related to this Agreement, whether grounded in tort (including negligence), strict liability, contract, or otherwise. 

 

	10.3	 Workers’ Compensation. LogicBio will comply with all statutory workers’
compensation and employers’ liability requirements for activities performed under this Agreement. 

  

	10.4	 Insurance. During the term of this Agreement, LogicBio will maintain Comprehensive General Liability
Insurance, including Product Liability Insurance, with a reputable and financially secure insurance carrier to cover the activities of LogicBio and its sublicensees. The insurance will provide minimum limits of liability of $[***] prior to the first
use of Licensed Product in human patients and $[***] commencing on the first use of Licensed Product in human patients and during the remaining term of this Agreement and will include all Stanford Indemnitees as additional insureds. Insurance must
cover claims incurred, discovered, manifested, or made during or after the expiration of this Agreement and must be placed with carriers with ratings of at least A- as rated by A.M. Best. Within [***] days of
the Effective Date of this Agreement, LogicBio will furnish a Certificate of Insurance evidencing primary coverage and additional insured requirements. LogicBio 

  
 PAGE 21
OF 29 
 [***] PORTIONS OF THIS EXHIBIT HAVE
BEEN REDACTED PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION
OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 EXECUTION VERSION 

 

	 	
will provide to Stanford [***] days prior written notice of cancellation or material change to this insurance coverage. LogicBio will advise Stanford in writing that it maintains excess liability
coverage (following form) over primary insurance for at least the minimum limits set forth above. All insurance of LogicBio will be primary coverage; insurance of Stanford Indemnitees will be excess and noncontributory. 

 

	11.	 EXPORT 

LogicBio and its affiliates and sublicensees shall comply with all United States laws and regulations controlling the export of licensed commodities and
technical data. (For the purpose of this paragraph, “licensed commodities” means any article, material or supply but does not include information; and “technical data” means tangible or intangible technical information that is
subject to U.S. export regulations, including blueprints, plans, diagrams, models, formulae, tables, engineering designs and specifications, manuals and instructions.) These laws and regulations may include, but are not limited to, the Export
Administration Regulations (15 CFR 730-774), the International Traffic in Arms Regulations (22 CFR 120-130) and the various economic sanctions regulations administered
by the U.S. Department of the Treasury (31 CFR 500-600). 
 Among other things, these laws and regulations prohibit
or require a license for the export or retransfer of certain commodities and technical data to specified countries, entities and persons. LogicBio hereby gives written assurance that it will comply with, and will cause its affiliates and
sublicensees to comply with all United States export control laws and regulations, that it bears sole responsibility for any violation of such laws and regulations by itself or its affiliates or sublicensees, and that it will indemnify, defend and
hold Stanford harmless for the consequences of any such violation. 
  

	12.	 MARKING 

Before any GT Licensed Patent or VT Licensed Patent issues, LogicBio will mark Licensed Product with the words “Patent Pending.” Otherwise, LogicBio
will mark Licensed Product with the number of any issued GT Licensed Patent or VT Licensed Patent. 
  

	13.	 STANFORD NAMES AND MARKS 

LogicBio will not use (i) Stanford’s name or other trademarks, (ii) the name or trademarks of any organization related to Stanford, or
(iii) the name of any Stanford faculty member, employee, student or volunteer without the prior written consent of Stanford. Permission may be withheld at Stanford’s sole discretion. This prohibition includes, but is not limited to, use in
press releases, advertising, marketing materials, other promotional materials, presentations, case studies, reports, websites, application or software interfaces, and other electronic media. Notwithstanding anything to the contrary herein, LogicBio
may without prior permission, reasonably utilize Stanford’s name or names of Stanford employees in statements of fact (provided such statements do not imply endorsement of LogicBio’s products or services) in legal proceedings, patent
filings, and regulatory filings. 

  
 PAGE 22
OF 29 
 [***] PORTIONS OF THIS EXHIBIT HAVE
BEEN REDACTED PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION
OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 EXECUTION VERSION 

 

	14.	 PROSECUTION AND PROTECTION OF PATENTS 

 

	14.1	 Patent Prosecution for GT Licensed Patents. Stanford will be responsible for and will keep LogicBio
reasonably informed as to the preparing, filing, and prosecuting and maintaining of GT Licensed Patents. LogicBio will receive copies of all documentation and substantive actions pertaining to the filing, prosecution, and maintenance of GT Licensed
Patents. LogicBio will have reasonable opportunities to participate in decision making and Stanford will give LogicBio a reasonable opportunity to comment on material documents filed with any patent office with respect to the GT Licensed Patents and
will consider in good faith and use reasonable efforts to incorporate LogicBio’s comments. Stanford will, at LogicBio’s request, file, prosecute and maintain GT Licensed Patents in foreign countries, if available. In the event LogicBio
decides that it no longer intends to pay for prosecution or maintenance of one or more GT Licensed Patents, LogicBio shall provide Stanford [***] months’ notice. Stanford may in its discretion continue to prosecute and maintain such GT Licensed
Patent(s) at its expense, in which case such Licensed Patent(s) shall no longer be covered by the licenses granted under this Agreement. 

  

	14.2	 Patent Costs. Within [***] days after receiving a statement from Stanford, or as otherwise provided
below, LogicBio will reimburse Stanford: 

  

	 	(A)	 within [***] business days of the Effective Date, $[***] to offset certain GT Licensed Patent’s patenting
expenses incurred by Stanford before the Effective Date; 

  

	 	(B)	 $[***] to offset other GT Licensed Patent’s patenting expenses, including any interference or
reexamination matters, incurred by Stanford before the Effective Date; and 

  

	 	(C)	 [***] ([***]%) of GT Licensed Patent’s reasonable out-of-pocket patenting expenses, including any interference or reexamination matters, incurred by Stanford after the Effective Date. 

In all instances, Stanford will pay the fees prescribed for large entities to the United States Patent and Trademark Office. 

 

	14.3	 Licensed Patents Infringement Procedure. LogicBio will promptly notify Stanford if it believes a third
party infringes a Licensed Patent or if a third party files a declaratory judgment action with respect to any Licensed Patent. Subject to Section 14.4 below, LogicBio shall have the right to institute a suit against or defend any declaratory
judgment action initiated by this third party with respect only to the GT Licensed Patents as provided in Section 14.6 through and including Section 14.8, if the below conditions are met, as applicable: 

 

	 	(A)	 For any action with respect to the GT Licensed Patents, LogicBio’s rights to the GT Licensed Patents are
still Exclusive; 

  
 PAGE 23
OF 29 
 [***] PORTIONS OF THIS EXHIBIT HAVE
BEEN REDACTED PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION
OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 EXECUTION VERSION 

 

	 	(B)	 For any infringement suit, as applicable, the suit is in the Therapeutics Field of Use or Tissue Field of Use
for GT Licensed Patents; 

  

	 	(C)	 LogicBio is developing or selling a Licensed Product based on the GT Licensed Patents in the Therapeutics Field
of Use or Tissue Field of Use; and 

  

	 	(D)	 LogicBio agrees to bear Stanford’s costs in accordance with Sections 14.5 and 14.6. 

If the above applicable conditions are not met, Sections 14.5-14.8 do not apply with respect to the applicable suit against or defense of any
declaratory judgment action initiated by the third party. If LogicBio still has an Exclusive license under the GT Licensed Patents in the Therapeutics Field of Use or Tissue Field of Use and is in good standing under this Agreement, Stanford will
not grant to any third party, or amend, change, or modify any rights of a third party, to enforce the applicable Licensed Patents or institute a suit against or defend any declaratory judgment action initiated by a third party with respect to the
Licensed Patents without the prior written consent of LogicBio. 
  

	14.4	 Stanford Suit. If LogicBio does not exercise its first right pursuant to Section 14.3 or Stanford
and the LogicBio do not agree to enter into a joint action pursuant to Section 14.5, then Stanford shall have the right to institute suit, and may name LogicBio as a party for standing purposes. If Stanford decides to institute suit, it will
notify LogicBio in writing. If LogicBio does not notify Stanford in writing that it desires to jointly prosecute the suit within 15 days after the date of the notice in accordance with Section 14.5, LogicBio will assign and hereby does assign
to Stanford all rights, causes of action, and damages resulting from the alleged infringement. Stanford will bear the entire cost of the litigation and, following reimbursement of any reasonable legal fees incurred by LogicBio in cooperating with
such action by Stanford, Stanford will retain the entire amount of any recovery or settlement. 

  

	14.5	 Joint Suit. If Stanford and LogicBio so agree, they may institute suit or defend the declaratory
judgment action jointly. If so, they will: 

  

	 	(A)	 prosecute the suit in both their names; 

 

	 	(B)	 bear the out-of-pocket costs
equally; 

  

	 	(C)	 share any recovery or settlement equally; and 

 

	 	(D)	 agree how they will exercise control over the action. 

 

	14.6	 LogicBio Suit. LogicBio shall have the first right to institute and prosecute a suit or defend any
declaratory judgment action so long as it conforms with the requirements of this Section and LogicBio is diligently developing or selling Licensed Product. LogicBio will diligently pursue the suit and LogicBio will bear the entire cost of the
litigation, including expenses and counsel fees incurred by Stanford. LogicBio will keep Stanford reasonably apprised of all developments in the suit, and will seek Stanford’s input and approval on any substantive submissions or positions taken
in the litigation regarding the 

  
 PAGE 24
OF 29 
 [***] PORTIONS OF THIS EXHIBIT HAVE
BEEN REDACTED PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION
OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 EXECUTION VERSION 

 

	 	
scope, validity and enforceability of the Licensed Patent. LogicBio will not prosecute, settle or otherwise compromise any such suit in a manner that adversely affects Stanford’s interests
without Stanford’s prior written consent. Stanford may be named as a party only if 

  

	 	(A)	 LogicBio’s and Stanford’s respective counsel recommend that such action is necessary in their
reasonable opinion to achieve standing; 

  

	 	(B)	 Stanford is not the first named party in the action; and 

 

	 	(C)	 the pleadings and any public statements about the action state that LogicBio is pursuing the action and that
LogicBio has the right to join Stanford as a party. 

  

	14.7	 Recovery. If LogicBio sues under Section 14.6, then any recovery in excess of any unrecovered
litigation costs and fees will be shared with Stanford as follows: 

  

	 	(A)	 any payment for past sales will be deemed Net Sales, and LogicBio will pay Stanford royalties at the rates
specified in Section 7.8; 

  

	 	(B)	 any payment for future sales will be deemed a payment under a Sublicense, and royalties will be shared as
specified in Article 4; and 

  

	 	(C)	 LogicBio and Stanford will negotiate in good faith appropriate compensation to Stanford for any non-cash settlement or non-cash cross-license. 

  

	14.8	 Abandonment of Suit. If either Stanford or LogicBio commences a suit and then wants to abandon the suit,
it will give timely notice to the other party. The other party may continue prosecution of the suit after Stanford and LogicBio agree on the sharing of expenses and any recovery in the suit. 

 

	15.	 TERMINATION 

  

	15.1	 Termination by LogicBio. LogicBio may terminate this Agreement by giving Stanford written notice at
least 30 days in advance of the effective date of termination selected by LogicBio. 

  

	15.2	 Termination by Stanford. 

 

	 	(A)	 Stanford may also terminate this Agreement on 60 days written notice if LogicBio: 

 

	 	(1)	 is in material default in the provision of any report or payment of amounts due; 

 

	 	(2)	 is not using commercially reasonable efforts in developing and/or commercializing Licensed Product;

  
 PAGE 25
OF 29 
 [***] PORTIONS OF THIS EXHIBIT HAVE
BEEN REDACTED PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION
OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 EXECUTION VERSION 

 

	 	(3)	 misses a milestone in Appendix C, subject to LogicBio’s right to extend the timeframe for milestones
pursuant to Section 6.1 and the rights set forth in Section 15.2(B); 

  

	 	(4)	 is in material breach of any provision; or 

 

	 	(5)	 provides any materially false report. 

 

	 	(B)	 Subject to LogicBio’s right to extend the timeframe for milestones pursuant to Section 6.1, in the
event LogicBio misses any of milestone numbers 4 through 8 in Appendix C for [***], but has met such milestone for an indication other than [***], Stanford may convert the license for [***] under this Agreement to
non-exclusive and effective upon such conversion, [***] will be included in the Non-Exclusive Field of Use. 

 

	 	(C)	 Termination under this Section 15.2 will take effect [***] days after written notice by Stanford unless
LogicBio remedies the specified default or breach in that [***] day period. 

  

	15.3	 Surviving Provisions. Surviving any termination or expiration are: 

 

	 	(A)	 LogicBio’s obligation to pay royalties accrued or accruable; 

 

	 	(B)	 any claim of LogicBio or Stanford, accrued or to accrue, because of any breach or default by the other party;
and 

  

	 	(C)	 the provisions of Sections 8.2 (No Refund), 8.3 (Termination Report), 8.4 (Accounting), and 15.3 (Surviving
Provisions), the second and third sentences of Section 7.14 (Obligation to Pay Royalties) upon expiration of the applicable royalty term described therein, and Articles 2 (Definitions), 9 (Exclusion and Negation of Warranties), 10 (Indemnity),
13 (Stanford Names and Marks), 17 (Dispute Resolution), and 19 (Miscellaneous). 

  

	 	(D)	 any Sublicenses granted hereunder, subject to the requirements of Sublicensees in Article 4.

  

	16.	 CHANGE OF CONTROL AND NON-ASSIGNABILITY 

 

	16.1	 Change of Control. If there is a Change of Control, LogicBio will pay Stanford $325,000 (“Change of
Control Fee”). 

  

	16.2	 Conditions of Assignment under Change of Control. LogicBio may assign or transfer this Agreement
(i) to an affiliate, or (ii) as part of a Change of Control upon prior and complete performance of the following conditions: 

  

	 	(A)	 LogicBio must give Stanford 15 days prior written notice of the assignment, including the new assignee’s
contact information; and 

  
 PAGE 26
OF 29 
 [***] PORTIONS OF THIS EXHIBIT HAVE
BEEN REDACTED PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION
OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 EXECUTION VERSION 

 

	 	(B)	 the new assignee must agree in writing to Stanford to be bound by this Agreement, or must succeed to
LogicBio’s rights and obligations under this Agreement by law; and 

  

	 	(C)	 Stanford must have received the full Change of Control Fee. 

 

	16.3	 After the Assignment. Upon a permitted assignment of this Agreement pursuant to Article 16, LogicBio
will be released of liability under this Agreement and the term “LogicBio” in this Agreement will mean the assignee. 

  

	16.4	 Bankruptcy. In the event of a bankruptcy or insolvency, assignment is permitted only to a party that can
provide adequate assurance of future performance, including diligent development and sales of Licensed Product. 

  

	16.5	 Nonassignability of Agreement. Except in conformity with Sections 16.2 and 16.4, this Agreement is not
assignable by LogicBio under any other circumstances and any attempt to assign this Agreement by LogicBio is null and void. 

  

	17.	 DISPUTE RESOLUTION 

 

	17.1	 Dispute Resolution by Arbitration. Any dispute between the parties regarding any payments made or due
(including without limitation for apportionment of Nonroyalty Sublicensing Consideration) under this Agreement will be settled by arbitration in accordance with the JAMS Arbitration Rules and Procedures; provided that in the case of a good faith
dispute as to the amount owed, LogicBio shall not be in breach of this Agreement and the cure period under Section 15.2 shall be tolled until the amount owed has been finally determined in such an arbitration. The parties are not obligated to
settle any other dispute that may arise under this Agreement by arbitration. 

  

	17.2	 Request for Arbitration. Either party may request such arbitration. Stanford and LogicBio will mutually
agree in writing on a third party arbitrator within 30 days of the arbitration request. The arbitrator’s decision will be final and nonappealable and may be entered in any court having jurisdiction. 

 

	17.3	 Discovery. The parties will be entitled to discovery as if the arbitration were a civil suit in the
California Superior Court. The arbitrator may limit the scope, time, and issues involved in discovery. 

  

	17.4	 Place of Arbitration. The arbitration will be held in Stanford, California unless the parties mutually
agree in writing to another place. 

  

	17.5	 Patent Validity. Any dispute regarding the validity of any Licensed Patent shall be litigated in the
courts located in Santa Clara County, California, and the parties agree not to challenge personal jurisdiction in that forum. 

  
 PAGE 27
OF 29 
 [***] PORTIONS OF THIS EXHIBIT HAVE
BEEN REDACTED PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION
OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 EXECUTION VERSION 

 

	18.	 NOTICES 

  

	18.1	 Legal Action. LogicBio will provide written notice to Stanford at least three months prior to bringing
an action seeking to invalidate any Licensed Patent or a declaration of non-infringement. LogicBio will include with such written notice an identification of all prior art it believes invalidates any claim of
the Licensed Patent. 

  

	18.2	 All Notices. All notices under this Agreement are deemed fully given when written, addressed, and sent
as follows: 

 All general notices to LogicBio are mailed or emailed to: 

LogicBio Therapeutics, Inc. 

Attention: Chief Business Officer 

700 Main Street, Cambridge, MA 02139 

twilton@logicbiotherapeutics.com 

All financial invoices to LogicBio (i.e., accounting contact) are mailed or e-mailed to: 

LogicBio Therapeutics, Inc. 

Attention: Chief Business Officer 

700 Main Street, Cambridge, MA 02139 

twilton@logicbiotherapeutics.com 

All progress report invoices to LogicBio (i.e., technical contact) are mailed or e-mailed to: 

LogicBio Therapeutics, Inc. 

Attention: Chief Business Officer 

700 Main Street, Cambridge, MA 02139 

twilton@logicbiotherapeutics.com 

All general notices to Stanford are e-mailed or mailed to: 

Office of Technology Licensing 

3000 El Camino Real 
 Building 5,
Suite 300 
 Palo Alto, CA 94306-2100 

info@otlmail.stanford.edu 
 All
payments to Stanford are mailed to: 
 Stanford University 

Office of Technology Licensing 

  
 PAGE 28
OF 29 
 [***] PORTIONS OF THIS EXHIBIT HAVE
BEEN REDACTED PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION
OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 EXECUTION VERSION 

 

 Department #44439 

P.O. Box 44000 
 San Francisco, CA
94144-4439 
 All progress reports to Stanford are e-mailed or mailed to: 

Office of Technology Licensing 

3000 El Camino Real 
 Building 5,
Suite 300 
 Palo Alto, CA 94306-2100 

info@otlmail.stanford.edu 
 Any
notice related to Section 7.4 (Purchase Right) or Section 7.5 (Rights Agreements; Information Rights; Notice; Elections) shall be copied concurrently to pvfnotices@stanford.edu. 

Either party may change its address with written notice to the other party. 

 

	19.	 MISCELLANEOUS 

 

	19.1	 Confidentiality. Stanford’s Office of Technology Licensing (“OTL”) shall maintain the
financial terms of this Agreement as well as the reports and any information provided by LogicBio to Stanford hereunder, including information provided pursuant to Sections 3.4 (Capsid Selection), 4.5 (Copy of Sublicenses and Sublicense Royalty
Reports), 6.3 (Progress Report), 7.6 (License Maintenance Fee), 8.1 (Quarterly Earned Royalty Payment and Report), 8.3 (Termination Report), 8.5 (Audit by Stanford), and 8.7 (Self-audit) of this Agreement, in confidence and not disclose such
information or reports to any third party, except as required by law. Stanford OTL’s obligation of confidentiality hereunder shall be fulfilled by using at least the same degree of care with LogicBio’s confidential information as Stanford
OTL uses to protect its own confidential information. However, Stanford OTL will have the right to disclose Confidential Information to legal counsel, public accountant, or agents who have a need to know such information and agree to be bound by the
confidentiality provisions herein. Additionally, Stanford OTL may report royalties in aggregate per Stanford’s normal reporting, report royalties to inventors of Licensed Patents per Stanford’s normal reporting and provide a copy of this
Agreement to the inventors of Licensed Patents under a confidential disclosure agreement. 

  

	19.2	 Waiver. No term of this Agreement can be waived except by the written consent of the party waiving
compliance. 

  

	19.3	 Choice of Law. This Agreement and any dispute arising under it is governed by the laws of the State of
California, United States of America, applicable to agreements negotiated, executed, and performed within California. 

  
 PAGE 29
OF 29 
 [***] PORTIONS OF THIS EXHIBIT HAVE
BEEN REDACTED PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION
OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 EXECUTION VERSION 

 

	19.4	 Entire Agreement. The parties have read this Agreement and agree to be bound by its terms, and further
agree that it constitutes the complete and entire agreement of the parties and supersedes all previous communications, oral or written, and all other communications between them relating to the license and to the subject hereof (including without
limitation the Prior Agreement). This Agreement may not be amended except by writing executed by authorized representatives of both parties. No representations or statements of any kind made by either party, which are not expressly stated herein,
will be binding on such party. 

  

	19.5	 Exclusive Forum. The state and federal courts having jurisdiction over Stanford, California, United
States of America, provide the exclusive forum for any court action between the parties relating to this Agreement. LogicBio submits to the jurisdiction of such courts, and waives any claim that such a court lacks jurisdiction over LogicBio or
constitutes an inconvenient or improper forum. 

  

	19.6	 Headings. No headings in this Agreement affect its interpretation. 

 

	19.7	 Electronic Copy. The parties to this document agree that a copy of the original signature (including an
electronic copy) may be used for any and all purposes for which the original signature may have been used. The parties further waive any right to challenge the admissibility or authenticity of this document in a court of law based solely on the
absence of an original signature. 

  
 PAGE 30
OF 29 
 [***] PORTIONS OF THIS EXHIBIT HAVE
BEEN REDACTED PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. AN UNREDACTED VERSION
OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 

 The parties execute this Agreement in duplicate originals by their duly authorized officers or
representatives. 
  

			
	THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

 
			
		
	Signature:	 	/s/ Mona Wan
	Name:	 	Mona Wan
	Title:	 	Associate Director

  

			
	LOGICBIO THERAPEUTICS, INC.

 
			
		
	Signature:	 	/s/ Frederic Chereau
	Name:	 	Frederic Chereau
	Title:	 	President & CEO

  

[SIGNATURE PAGE TO AMENDED AND RESTATED
EXCLUSIVE (EQUITY) AGREEMENT] 

 Appendix A—GT Licensed Patents 

 

															
	 Docket
	 	 Assoc
	 	 Country
	 	 Type
	 	 Related Patent
	 	 Status
	 	 Serial#
	 	 Filed

	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

 Appendix B—VT Licensed Patents 

 

															
	 	 	 Docket
	 	 Country
	 	 Type
	 	 Serial#
	 	 Patent#
	 	 Filed
	 	 Granted

	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	
		 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	
		 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	
		 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	
		 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	
		 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
		 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	
		 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	
		 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	
	 [***]
	 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	
		 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	
		 	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	

 Appendix C—Milestones 

 

	 	1.	 [***] 

	 	2.	 [***] 

	 	3.	 [***] 

	 	4.	 [***] 

	 	5.	 [***] 

	 	6.	 [***] 

	 	7.	 [***] 

	 	8.	 [***] 

	 	9.	 [***] 

	 	10.	 [***] 

Product 2 
  

	 	1.	 [***] 

	 	2.	 [***] 

	 	3.	 [***] 

	 	4.	 [***] 

	 	5.	 [***] 

	 	6.	 [***] 

Product 3 
  

	 	1.	 [***] 

	 	2.	 [***] 

	 	3.	 [***] 

	 	4.	 [***] 

	 	5.	 [***] 

	 	6.	 [***] 

[***] Field Milestones 
  

	 	1.	 [***] 

	 	2.	 [***] 

	 	3.	 [***] 

	 	4.	 [***] 

	 	5.	 [***] 

	 	6.	 [***] 

 Appendix D—Sample Reporting Form 

Stanford Docket No. S    - 
 This report is
provided pursuant to the license agreement between Stanford University and (LogicBio Name) 
 License Agreement Effective Date: 

Name(s) of Licensed Products being reported: 
  

					
	 Report Covering Period
	  			
	 Yearly Maintenance Fee
	  	$	 	 
	 Number of Sublicenses Executed
	  			
	 Gross Revenue
	  			
	 U.S. Gross Revenue
	  	$	 	 
	 Non-U.S. Gross Revenue
	  	$	 	 
	 Net Sales
	  			
	 U.S. Net Sales
	  	$	             	 
	 Non-U.S. Net Sales
	  	$	 	 
	 Royalty Calculation
	  			
	 Royalty Subtotal
	  	$	 	 
	 Credit
	  	$	 	 
	 Royalty Due
	  	$	 	 

 Name(s) of Sublicenses being reported: 

Calculation of Nonroyalty Sublicensing Consideration: 
 Comments:

 Appendix E—Technology 

[***]EX-10.2

 Exhibit 10.2 

CONFIDENTIAL 

Execution Version 

PATENT & TECHNOLOGY LICENSE AGREEMENT 

AGT. NO. L2549-LogicBio 
 This Patent and
Technology License Agreement (“Agreement”) is between The Board of Regents (“Board”) of The University of Texas System (“System”), an agency of the State of Texas whose address is 201 West 7th Street, Austin, Texas
78701 on behalf of The University of Texas Southwestern Medical Center (“UT Southwestern”), a component institution of System, whose address is 5323 Harry Hines Boulevard, Dallas, Texas 75390-9094 (“Licensor”) and LogicBio
Therapeutics, Inc., a Delaware corporation, with its principal place of business at 700 Main Street, Cambridge, MA 02139 (“Licensee”) (collectively, “Parties”, or singly, “Party”). 

This Agreement has an “Effective Date” of: May 7, 2018. 

No binding agreement between the Parties will exist until the Agreement has been signed by both Parties. Unsigned drafts of the Agreement shall not be
considered offers. 
 Background 

Licensor and The Board of Trustees of the Leland Stanford Junior University are joint owners of the rights in the patents and/or patent applications identified
in EXHIBIT A to the Agreement. Licensor owns or controls Licensed Subject Matter (defined below). Licensee desires to secure the right and license to use, develop, manufacture, market, and commercialize the Licensed Subject Matter. Licensor has
determined that such use, development, and commercialization of the Licensed Subject Matter is in the public’s best interest and is consistent with Licensor’s educational and research missions and goals. Licensor desires to have the
Licensed Subject Matter developed and used for the benefit of Licensee, the inventors, Licensor, and the public. 
 The Parties entered into that certain
Option Agreement, dated as of October 17, 2016 (the “Option Agreement”). 
 Licensee has exercised its option to negotiate a license in
accordance with the terms set forth in the Option Agreement. 
 NOW, THEREFORE, in consideration of the mutual covenants and premises herein contained, the
Parties hereby agree as follows: 
  

	1.	 Definitions 

Unless specifically defined elsewhere in this Agreement, the following terms, whether used in the singular or plural, shall have the respective
meanings set forth below: 
 “Active Indication” has the meaning set forth in Section 2.4. 

“Affiliate” means any business entity more than 50% owned by Licensee, any business entity which owns more than 50% of
Licensee, or any business entity that is more than 50% owned by a business entity that owns more than 50% of Licensee. 

  

					
	 Licensee: LogicBio Therapeutics, Inc.
 Licensor:
UT Southwestern Medical Center
	  	CONFIDENTIAL	  	 Exclusive License

Page 1 of 33

[***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An un-redacted version of this exhibit has
been filed separately with the commission. 

 Execution Version 

 

 “Agreement” has the meaning set forth in the Preamble. 

“Annual Payment Deadline” means the day that is [***] days after the last day of any particular Contract Year. 

“Board” has the meaning set forth in the Preamble. 

“Confidential Information” has the meaning set forth in Section 8.1. 

“Contract Quarter” means the three-month periods ending on March 31, June 30, September 30 and
December 31, or any stub period thereof at the commencement of the Agreement or the expiration or termination of the Agreement. 

“Contract Year” means the 12-month periods ending on December 31, or any stub
period thereof at the commencement of the Agreement or the expiration or termination of the Agreement. 
 “Diligence Milestone
Event” means all events identified as Milestone Events in Section 2.7. 
 “Fair Market Value” means the cash
consideration an unaffiliated, unrelated buyer would pay in an arm’s length sale of a substantially identical item sold in the same quantity, under the same terms, and at the same time and place. 

“FDA” means United States Food and Drug Administration, or any successor entity thereof. 

“Field” means the Tissue Field and Therapeutics Field. 

“Government” means any agency, department or other unit of the United States of America or the State of Texas. 

“Gross Consideration” means all cash and non-cash consideration (e.g., securities).

 “Indemnified Parties” has the meaning set forth in Section 13.1. 

“Inventors” (or singly, “Inventor”) means Matthew Porteus, Josh Checketts, and Richard Voit, who were
employees of UT Southwestern, and later of Stanford University, whose address is 450 Serra Mall, Stanford, California 94305–2004 (“Stanford”), at the time Licensed Subject Matter was developed, Jenny Barker, who was an employee
of UT Southwestern at the time Licensed Subject Matter was developed, and Mark A. Kay and Adi Barzel, who were employees of Stanford at the time Licensed Subject Matter was developed.  

“Liabilities” has the meaning set forth in Section 13.1. 

“Licensed Process” means a method or process whose practice or use is covered by a Valid Claim or uses Technology Rights. 

“Licensed Product” means 1) any product or component whose manufacture, use, sale, offer for sale or import is covered by any
Valid Claim or incorporates any Technology Rights, or 2) any 

  

					
	 Licensee: LogicBio Therapeutics, Inc.
 Licensor:
UT Southwestern Medical Center
	  	CONFIDENTIAL	  	 Exclusive License

Page 2 of 33

[***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An un-redacted version of this exhibit has
been filed separately with the commission. 

 Execution Version 

 

 
service whose practice, performance, sale, offer for sale or import is covered by any Valid Claim or incorporates any Technology Rights, or uses any Licensed Product, or involves the practice of
a Licensed Process. 
 “Licensed Subject Matter” means Patent Rights and/or Technology Rights. 

“Licensee” has the meaning set forth in the Preamble. 

“Licensor” has the meaning set forth in the Preamble. 

“Milestone Event” means all events identified as Milestone Events in Section 3.1(a). 

“Milestone Fees” means all fees identified as Milestone Fees in Section 3.1(a). 

“Net Sales” means the Gross Consideration from the Sale of Licensed Products less the following items directly attributable to
the Sale of such Licensed Products that are specifically identified on the invoice for such Sale and borne by the Licensee, Affiliates, or Sublicensees as the seller: (a) discounts and rebates actually granted; (b) sales, value added, use
and other taxes and government charges actually paid, excluding income taxes; (c) import and export duties actually paid; (d) outbound freight, shipping or transportation costs, and costs of insurance in transit, actually paid or allowed;
and (e) other amounts actually refunded, allowed or credited due to rejections, recalls or returns, but not exceeding the original invoiced amount. Net Sales exclude a reasonable quantity used internally solely for testing or quality control
purposes, marketing or demonstration purposes, or seeking governmental approval (e.g., FDA clinical trial). In the case of any Sale or other transfer of a Licensed Product within Licensee or among Licensee, a Sublicensee or their Affiliates for
further sale or other transfer by such transferee, Net Sales shall be based on the Gross Consideration received for the first Sale to an entity other than Licensee, a Sublicensee or their Affiliates. Notwithstanding the foregoing, transfers or other
dispositions of Licensed Products at cost (i) in connection with patient assistance programs, (ii) for charitable or promotional purposes or (iii) for pre-clinical, regulatory or governmental
purposes or under “named patient” or other similar limited access programs shall not result in Net Sales. 
 In the event that a
Licensed Product is sold or provided in combination with another product, component or service for which no royalty would be due hereunder if sold or provided separately, Net Sales from such combination sales for purposes of calculating the amount
of royalties due under Section 3.2 shall be calculated by multiplying the Net Sales of the combination product or service by the fraction A/(A + B), where A is the average Gross Consideration during the preceding Contract Quarter of the
Licensed Product sold or provided separately and B is the average gross selling price during the preceding Contract Quarter of the other product(s), component(s) or service(s). In the event that separate sales of the Licensed Product and/or of the
other product(s), component(s) or service(s) were not made during the preceding Contract Quarter, then the Net Sales on the combination product or service shall be reasonably allocated between such Licensed Product and such other product(s),
component(s) or service(s) based upon their relative importance and proprietary protection as mutually agreed upon by the Parties. 

  

					
	 Licensee: LogicBio Therapeutics, Inc.
 Licensor:
UT Southwestern Medical Center
	  	CONFIDENTIAL	  	 Exclusive License

Page 3 of 33

[***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An un-redacted version of this exhibit has
been filed separately with the commission. 

 Execution Version 

 

 “New License Agreement” has the meaning set forth in Section 7.5(a).

 “Nominated Tissues” has the meaning set forth in Section 2.3. 

“Non-Royalty Sublicensing Consideration” means the Gross Consideration received by the
Licensee or its Affiliate from a Sublicensee in consideration of the grant of a sublicense under the Licensed Subject Matter (including, without limitation, license or option or distribution fees, fees to maintain license rights, and bonus/milestone
payments), but excluding amounts received as running royalties, a profit share, other revenue sharing based on Net Sales for which Licensor receives a running royalty under Section 3.2, purchase price for the issuance of stock or other equity
or debt securities to the extent issued at Fair Market Value, payments designated by Sublicensee for the purpose of funding or reimbursing bona fide research, development, or commercialization, payments for manufacture or supply of Licensed Product
at cost, reimbursements of patent expenses actually incurred by Licensee, and loans. For the avoidance of doubt, Non-Royalty Sublicensing Consideration shall not include bona fide: (a) running royalties
received by Licensee or an Affiliate based on Net Sales that are royalty-bearing to Licensor under Section 3.2, (b) purchase price for Licensee’s stock or other securities not in excess of Fair Market Value. 

“Party” or “Parties” has the meaning set forth in the Preamble. 

“Patent Rights” means the Licensor’s rights in (a) the patents and patent applications listed in EXHIBIT A to the
Agreement; (b) all non-provisional patent applications that claim priority to any provisional application listed in EXHIBIT A to the Agreement to the extent the claims of such non-provisional applications are entitled to claim priority to the aforesaid provisional patent applications; and (c) all divisionals, continuations, and such claims of continuations-in-part as are entitled to claim priority to the aforesaid patents and/or patent applications, and all reissues, reexaminations, extensions of, and foreign counterparts; and (d) any patents
that issue with respect to the aforesaid patent applications and any reissues, reexaminations or extensions thereof. From time to time during the term of the Agreement, upon written agreement by both Parties, Licensee and Licensor shall update the
list of all patent applications and patents within the Patent Rights. 
 “Prosecution Counsel” means the law firm or
attorney who is handling the prosecution of the Patent Rights. Prosecution Counsel as of the Effective Date is identified in EXHIBIT A to the Agreement. 

“Quarterly Payment Deadline” means the day that is [***] days after the last day of any particular Contract Quarter. 

“Regulatory Approval” means, with respect to a country, all approvals needed by the applicable Regulatory Authority for a
particular national jurisdiction to market, Sell and use a Licensed Product in that national jurisdiction. 
 “Regulatory
Authority” means the governmental authority responsible for granting any necessary licenses or approvals for the Marketing, Sale and use of a Licensed Product in a particular national jurisdiction, including without limitation FDA, European
Medicines Agency or Koseisho (i.e. the Japanese Ministry of Health and Welfare). 

  

					
	 Licensee: LogicBio Therapeutics, Inc.
 Licensor:
UT Southwestern Medical Center
	  	CONFIDENTIAL	  	 Exclusive License

Page 4 of 33

[***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An un-redacted version of this exhibit has
been filed separately with the commission. 

 Execution Version 

 

 “Royalty Term” means, with respect to a Licensed Product and a country, the
period that will commence with the first commercial Sale (following Regulatory Approval) of such Licensed Product in such country and continue until the later of (a) expiration or termination of the last to expire Valid Claim of a Patent Right
that would, but for the license granted here, be infringed by the manufacture, use, Sale, offer for Sale or import of such Licensed Product in such country, or (b) 10 years from the date of the first commercial sale of such Licensed Product in such
country. 
 “Sell, Sale or Sold” means any transfer or other disposition of Licensed Products to any third party for
which consideration is received by Licensee, its Affiliates or Sublicensees. A Sale of Licensed Products will be deemed completed at the time Licensee or its Affiliate or its Sublicensee receives such consideration. 

“Sublicense Agreement” means any agreement or arrangement pursuant to which Licensee (or an Affiliate or Sublicensee) grants
to any third party any of the license rights granted to the Licensee under the Agreement. 
 “Sublicense Fee” means the fee
specified in Section 3.1(c). 
 “Sublicensee” means any entity to whom an express sublicense has been granted under the
Patent Rights and/or Technology Rights. For clarity, a third party wholesaler or distributor who has no significant responsibility for marketing and promotion of the Licensed Product within its distribution territory or field (i.e., the third party
simply functions as a reseller), and who does not pay any consideration to Licensee or an Affiliate for such wholesale or distributor rights, shall not be deemed a Sublicensee; and the resale by such a wholesaler or distributor shall not be treated
as royalty bearing Net Sales by a Sublicensee provided that a royalty is being paid by Licensee for the initial transfer to the wholesaler or distributor pursuant to Section 3.2. This definition does not limit Licensee’s rights to grant or
authorize sublicenses under the Agreement. 
 “System” has the meaning set forth in the Preamble. 

“Technology Rights” means Licensor’s rights in technical information, know-how,
processes, procedures, compositions, devices, methods, formulas, protocols, techniques, designs, drawings or data created before the Effective Date by Inventors at the institutions(s) indicated in the definition of Inventors and within the Field
which are not covered by a Valid Claim but which are necessary or useful for practicing the Patent Rights. 
 “Territory”
means worldwide. 
 “Therapeutics Field” means human therapeutics to treat methylmalonic and propionic acidemia, HIV,
influenza, malaria, Crigler Najjar Syndrome, Tyrosinemia Type I, Wilson’s disease, hemophilia B, and Glycogen Storage Disease 1 and Glycogen Storage Disease 3, and any other human disease of liver tissue that affects less than 200,000 persons
in the United States as of the Effective Date. 
 “Tissue Field” means: 

  

					
	 Licensee: LogicBio Therapeutics, Inc.
 Licensor:
UT Southwestern Medical Center
	  	CONFIDENTIAL	  	 Exclusive License

Page 5 of 33

[***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An un-redacted version of this exhibit has
been filed separately with the commission. 

 Execution Version 

 

	 	(a)	 prior to the [***] anniversary of the Effective Date: 

 

	 	(1)	 the prevention, treatment or diagnosis of human disease via genome editing without a nuclease.

  

	 	(b)	 following the [***] anniversary of the Effective Date and until the [***] anniversary thereof:

  

	 	(1)	 the prevention, treatment or diagnosis of human disease of the Nominated Tissues via genome editing without a
nuclease. 

  

	 	(c)	 following the [***] anniversary of the Effective Date: 

 

	 	(1)	 the prevention, treatment or diagnosis of Active Indications via genome editing without a nuclease.

 “UT Southwestern” has the meaning set forth in the Preamble. 

“Valid Claim” means a claim of (i) an issued and unexpired patent included within the Patent Rights unless the claim has
been held unenforceable or invalid by the final, un-reversed, and un-appealable decision of a court or other government body of competent jurisdiction, has been
irretrievably abandoned or disclaimed, or has otherwise been finally admitted or determined to be invalid, un-patentable, or unenforceable, whether through reissue, reexamination, disclaimer or otherwise, or
(ii) a pending patent application within the Patent Rights, which has not been irrevocably cancelled, withdrawn or abandoned, provided that, if a claim of pending patent application has not issued as a claim of an issued patent within [***]
years after the filing date from which such claim takes priority, then such pending claim shall not be a Valid Claim for purposes of this Agreement. 
  

	2.	 License Grant and Commercialization 

 

	 	2.1	 Grant. 

  

	 	(a)	 Licensor grants to Licensee a royalty-bearing exclusive license (sublicensable through multiple tiers in
accordance with Section 2.6) under Patent Rights to manufacture, have manufactured, distribute, have distributed, use, offer for Sale, Sell, lease, loan and/or import Licensed Products in the Field in the Territory. 

 

	 	(b)	 Licensor grants to Licensee a royalty-bearing non-exclusive license
(sublicensable through multiple tiers in accordance with Section 2.6) under Technology Rights to manufacture, have manufactured, distribute, have distributed, use, offer for Sale, Sell, lease, loan and/or import Licensed Products in the Field
in the Territory. 

  

	 	(c)	 This grant is subject to (i) the payment by Licensee to Licensor of all consideration required under this
Agreement (provided that, for the avoidance 

  

					
	 Licensee: LogicBio Therapeutics, Inc.
 Licensor:
UT Southwestern Medical Center
	  	CONFIDENTIAL	  	 Exclusive License

Page 6 of 33

[***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An un-redacted version of this exhibit has
been filed separately with the commission. 

 Execution Version 

 

	 	
of doubt, this grant shall in any event continue until the termination or expiration of this Agreement in accordance with Section 7 of this Agreement), (ii) any rights of, or obligations to,
the Government as set forth in Section 11.2 (Government Rights), and (iii) rights retained by Licensor to: 

  

	 	(1)	 Publish the scientific findings from research related to the Patent Rights; and 

	 	

	 	(2)	 Use the Licensed Subject Matter for teaching, research, patient care, education, and other
educationally-related purposes; and 

  

	 	(3)	 Grant rights to, and transfer material embodiments of, the Licensed Subject Matter to other academic
institutions or non-profit research institutions for the purposes identified in clauses (1) and (2) above. 

  

	 	(d)	 Licensor reserves all rights not expressly granted in the Agreement and disclaims the grant of any implied
rights to Licensee. 

  

	 	2.2	 Affiliates. 

Licensee may extend the license granted herein to any Affiliate provided that the Affiliate agrees in writing to be bound by the Agreement to
the same extent as Licensee. For the sake of clarity, any specific reference to “Licensee” herein shall include such Affiliate regardless of whether a specific reference to an “Affiliate” is made in such provision. Licensee
agrees to deliver such written agreement to Licensor within [***] calendar days following execution. 
  

	 	2.3	 Nomination of Tissues. 

At any time prior to the [***] anniversary of the Effective Date, Licensee may provide to Licensor a written notice listing up to [***] human
tissues that will be the subject of Licensee’s development efforts with respect to the Licensed Subject Matter. By way of example, and without limiting the foregoing, for purposes of this Agreement, “human tissue”
includes tissues such as skeletal muscle tissue, lung tissue or the central nervous system. Beginning on the date on which Licensee provides such written notice to Licensor, such tissues shall be deemed “Nominated Tissues.” If Licensee
provides no such written notice to Licensor in accordance with this Section 2.3, no tissues will be deemed Nominated Tissues under this Agreement. 
  

	 	2.4	 Active Indications. 

On or before the [***] anniversary of the Effective Date, Licensee will provide to Licensor a written notice listing all indications that relate to the
Nominated Tissues that are the subject of Licensee’s research and development efforts with respect to the technology licensed under this Agreement as of the [***] anniversary of the Effective Date. Beginning on the third anniversary of the
Effective Date, such indications shall be deemed “Active Indications.” 

  

					
	 Licensee: LogicBio Therapeutics, Inc.
 Licensor:
UT Southwestern Medical Center
	  	CONFIDENTIAL	  	 Exclusive License

Page 7 of 33

[***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An un-redacted version of this exhibit has
been filed separately with the commission. 

 Execution Version 

 

	 	2.5	 Notification of Third Party Licenses. 

Commencing on the Effective Date for a period of [***] years, Licensor will provide prompt written notice to Licensee in the event that
Licensor enters into any discussions or negotiations with a third party regarding a license under the Patent Rights for in vivo applications in the prevention, treatment or diagnosis of human diseases. 

 

	 	2.6	 Sublicensing. 

Licensee has the right to grant Sublicense Agreements under the Licensed Subject Matter consistent with the terms of the Agreement, subject to
the following: 
  

	 	(a)	 A Sublicense Agreement shall not exceed the scope and rights granted to Licensee hereunder. Sublicensee must
agree in writing to be bound by the applicable terms and conditions of the Agreement. In the event of termination of this Agreement, continued sublicense rights shall be governed by Section 7.5(a) (Effect of Termination). Licensee may grant a
Sublicensee the right to grant further sub-Sublicense Agreements, in which case such sub-Sublicense Agreements shall be treated as “Sublicense Agreements” and
such sub-Sublicensees shall be treated as “Sublicensees” for purposes of the Agreement. 

  

	 	(b)	 Licensee shall deliver to Licensor a true and correct copy of each Sublicense Agreement granted by Licensee,
Affiliate or Sublicensee, and any modification or termination thereof, within [***] days following the applicable execution, modification, or termination of such Sublicense Agreement, which copy may be redacted to omit confidential information of
Licensee or its Sublicensee that is not necessary for Licensor to determine compliance with this Agreement. If the Sublicense Agreement is not in English, Licensee shall provide Licensor an accurate English translation in addition to a copy of the
original agreement. 

  

	 	(c)	 Notwithstanding any such Sublicense Agreement, Licensee will remain primarily liable to Licensor for all of the
Licensee’s duties and obligations contained in the Agreement, including without limitation the payment of running royalties due under Section 3.2 whether or not paid to Licensee by a Sublicensee. Any act or omission of a Sublicensee that
would be a breach of the Agreement if performed by Licensee will be deemed to be a breach by Licensee. Each Sublicense Agreement will contain a right of termination by Licensee in the event that the Sublicensee breaches the payment or reporting
obligations affecting Licensor or any other terms and conditions of the Sublicense Agreement that would constitute a breach of the Agreement if such acts were performed by Licensee. 

  

					
	 Licensee: LogicBio Therapeutics, Inc.
 Licensor:
UT Southwestern Medical Center
	  	CONFIDENTIAL	  	 Exclusive License

Page 8 of 33

[***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An un-redacted version of this exhibit has
been filed separately with the commission. 

 Execution Version 

 

	 	2.7	 Diligent Commercialization. 

Licensee by itself or through its Affiliates and Sublicensees will use commercially reasonable efforts to make a Licensed Product commercially
available in the Field within the Territory. Without limiting the foregoing, Licensee will 
  

	 	(a)	 maintain a bona fide, funded, ongoing and active research, development, manufacturing, regulatory, marketing or
sales program (all as commercially reasonable) to make a Licensed Product commercially available to the public as soon as commercially practicable, and 

  

	 	(b)	 fulfill the following milestone events by the deadlines indicated: 

 

					
	 Diligence Milestone Events
	  	 Deadlines
	 
	 [***]
	  	 	[***]	 
	 [***]
	  	 	[***]	 
	 [***]
	  	 	[***]	 
	 [***]
	  	 	[***]	 
	 [***]
	  	 	[***]	 

 If the obligations under this Section 2.7 are not fulfilled, Licensor may treat such failure as a breach
in accordance with Section 7.3(b). For the avoidance of doubt, initiation of a clinical trial means the dosing of the first patient in said clinical trial. 

Notwithstanding the foregoing, if Licensee believes that, despite using commercially reasonably efforts, it will not achieve any Diligence
Milestone Event set forth in this Section 2.7 by the relevant deadline, it may notify Licensor in writing thereof in advance of the deadline. Licensee shall include with such notice a reasonable explanation of the reasons for such failure. If
Licensee so notifies Licensor and such explanation is acceptable to Licensor (in its reasonable discretion), or, in any event, if such failure to meet the Diligence Milestone Event is due to circumstances beyond Licensee’s reasonable control
(such as patent infringement or regulatory issues), then the Parties shall negotiate in good faith an initial extension of the deadlines for said Diligence Milestone Event and all later Diligence Milestone Events (the “Initial Extended
Milestones”) so that Licensee shall not be deemed to be in breach of achieving said Diligence Milestone Event by its deadline. In the event that Licensee believes that, despite using commercially reasonable efforts, it will not achieve one or
more such Initial Extended Milestones, then Licensee may notify Licensor in writing thereof in advance of the relevant deadline and the Parties shall negotiate in good faith a second extension of deadlines for said Diligence Milestone Event and all
later Diligence Milestone Events (the “Second Extended Milestones”) so that Licensee shall not be deemed to be in breach of achieving said Diligence Milestone Event by its deadline. Upon agreement of the Parties with respect to the
deadlines for such Second Extended Milestones, Licensee shall make a non-creditable payment of one-half of the Milestone Fee of the Milestone Event corresponding to said
Diligence Milestone Event. 

  

					
	 Licensee: LogicBio Therapeutics, Inc.
 Licensor:
UT Southwestern Medical Center
	  	CONFIDENTIAL	  	 Exclusive License

Page 9 of 33

[***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An un-redacted version of this exhibit has
been filed separately with the commission. 

 Execution Version 

 

	3.	 Compensation 

In consideration of rights granted to Licensee, Licensee will pay Licensor the following fees and royalties. All fees and royalties are not
refundable and are not creditable against other fees and royalties. Each payment will reference the Agreement number and will be sent to Licensor’s payment and accounting contact in Section 18 (Notices). 

 

	 	3.1	 Non-Royalty Payments due from Licensee. 

 

	 	(a)	 Milestone Fees. 

Licensee will pay the Milestone Fee corresponding to the Milestone Event listed below upon the first occurrence of said Milestone Event
(regardless of the number of Licensed Products that achieve a particular Milestone Event), such payment being due on the Quarterly Payment Deadline for the Contract Quarter in which such Milestone Event occurs: 

 

					
	 Milestone Events
	  	
Milestone Fees
	 
	 [***]
	  	 	[***]	 
	 [***]
	  	 	[***]	 
	 [***]
	  	 	[***]	 
	 [***]
	  	 	[***]	 
	 [***]
	  	 	[***]	 
	 [***]
	  	 	[***]	 
	 [***]
	  	 	[***]	 
	 [***]
	  	 	[***]	 
	 [***]
	  	 	[***]	 
	 [***]
	  	 	[***]	 

 For the avoidance of doubt, initiation of a clinical trial means the dosing of the first patient in said
clinical trial. 
  

	 	(b)	 Scheduled License Fees. Licensee will pay license fees in the following amounts in accordance with the
following schedule: 

  

	 	(i)	 A license issue fee of $25,000 due and payable within [***] days after the Effective Date.

  

					
	 Licensee: LogicBio Therapeutics, Inc.
 Licensor:
UT Southwestern Medical Center
	  	CONFIDENTIAL	  	 Exclusive License

Page 10 of 33

[***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An un-redacted version of this exhibit has
been filed separately with the commission. 

 Execution Version 

 

	 	(ii)	 An annual license maintenance fee in the amount of $[***] due and payable on or before each Annual Payment
Deadline, which annual license maintenance fee shall be fully creditable against royalties owed to Licensor under Section 3.2 of this Agreement on such Annual Payment Deadline. 

 

	 	(c)	 Sublicense Fees. Licensee will pay sublicense fees (“Sublicense Fees”) on or before the
Quarterly Payment Deadline for the Contract Quarter in which Non-Royalty Sublicensing Consideration is received in an amount equal to the following: 

[***]% of any Non-Royalty Sublicensing Consideration received by Licensee if Sublicense Agreement is
executed prior to an IND clearance of the first Licensed Product. 
 [***]% of any Non-Royalty
Sublicensing Consideration received by Licensee if Sublicense Agreement is executed after IND clearance of the first Licensed Product and before first Regulatory Approval of a Licensed Product. 

[***]% of any Non-Royalty Sublicensing Consideration received by Licensee if Sublicense Agreement is
executed after first Regulatory Approval of the first Licensed Product. 
  

	 	(d)	 Assignment Fee. Licensee will pay the assignment fee equal to $[***] within [***] days of an assignment
of the Agreement per Section 15. 

  

	 	3.2	 Royalties. 

On a Licensed Product-by-Licensed Product and country-by-country basis, Licensee will pay Licensor earned running royalties on annual Net Sales of Licensed Products in each Contract Year during the applicable Royalty Term
as follows: 
  

			
	 Annual worldwide Net Sales of Licensed
Products in a Contract Year
	  	 Royalty Rate

	£$[***]	  	[***]%
	>$[***], £$[***]	  	[***]%
	>$[***], £$[***]	  	[***]%
	>$[***]	  	[***]%

 The Parties acknowledge that the earned royalties specified above shall be determined on a Licensed Product-by-Licensed Product and country-by-country basis. The earned royalty specified above
will be payable on or before the Annual Payment Deadline for such Contract Year, and will be subject to the following: 
  

	 	(a)	 No more than one royalty shall be paid to Licensor hereunder with respect to the Sale of any one unit of
Licensed Product, whether or not more than one Valid Claim is applicable to the Licensed Product, or the development, manufacture, or performance thereof. 

  

					
	 Licensee: LogicBio Therapeutics, Inc.
 Licensor:
UT Southwestern Medical Center
	  	CONFIDENTIAL	  	 Exclusive License

Page 11 of 33

[***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An un-redacted version of this exhibit has
been filed separately with the commission. 

 Execution Version 

 

	 	(b)	 No royalty shall be payable under this Section 3.2 with respect to (i) the Sale of Licensed Products
between or among Licensee, its Affiliates, and Sublicensees for re-sale purposes, provided Licensor is paid a royalty with respect to the re-sale, or (ii) payments
that constitute Non-Royalty Sublicensing Consideration. 

  

	 	(c)	 if a Licensed Product is not covered by a Valid Claim at the time of Sale in the jurisdiction of Sale, then the
royalty rates specified in this Section 3.2 may be reduced to [***]% of Net Sales. 

  

	 	3.3	 Royalty Stacking. 

If, during the term of this Agreement, Licensee, its Affiliate(s), or Sublicensee(s) makes royalty, milestone or other payments to any third
party (other than a Sublicensee) who owns or controls any technology or intellectual property rights that are necessary for the manufacturing and/or selling of a Licensed Product in consideration for a license under or acquisition of such technology
or intellectual property rights, then [***]% of any such royalty payments shall be deductible from any royalty payments due to Licensor. However, in no event shall such adjustment result in royalty payments due to Licensor being reduced by more than
[***]% of the royalty stated in Section 3.2 in any Contract Year. 
  

	 	3.4	 Non-cash Consideration. 

If Licensee receives or anticipates receipt of non-cash consideration from Sales or Sublicenses, the
manner in which Licensor will receive its compensation under the Agreement with respect to such non-cash consideration will be negotiated in good faith and timely agreed to by the Parties. 

 

	4.	 Reports and Plans 

The reports specified in this Section 4 will be sent to Licensor’s payment and reporting contact identified in Section 18
(Notices). If Licensor requests to have information submitted in a particular format, Licensee will use reasonable efforts to comply with such request. 
  

	 	4.1	 Annual Payment and Milestone Reports. 

Immediately starting after the first Sale of a Licensed Product and thereafter, on or before each Annual Payment Deadline, Licensee will
deliver to Licensor a true and accurate report certified by an officer of Licensee, giving such particulars of the business conducted by Licensee, its Affiliates and its Sublicensees (including copies of reports provided by Sublicensees and
Affiliates to Licensee) during the preceding Contract Year under the Agreement as necessary for Licensor to account for Licensee’s payments, including royalties, hereunder, even if no payments are due. The reports shall continue to be delivered
after the termination or expiration of the Agreement until such time as 

  

					
	 Licensee: LogicBio Therapeutics, Inc.
 Licensor:
UT Southwestern Medical Center
	  	CONFIDENTIAL	  	 Exclusive License

Page 12 of 33

[***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An un-redacted version of this exhibit has
been filed separately with the commission. 

 Execution Version 

 

 
all Licensed Products permitted to be Sold after termination or expiration have been Sold or destroyed. The report shall include: 

 

	 	(a)	 The name of the Licensee, the Agreement number, and the period covered by the report; 

 

	 	(b)	 The name of any Affiliates and Sublicensees whose activities are also covered by the report;

  

	 	(c)	 Identification of each Licensed Product for which any royalty payments have become payable;

  

	 	(d)	 Net Sales segregated on a
product-by-product basis, and a country-by-country basis, or an affirmative statement
that no Sales were made. The report shall also itemize the permitted deductions from the Gross Consideration used to arrive at the resulting Net Sales, on a
product-by-product and country-by-country basis; 

 

	 	(e)	 The applicable royalty rate; 

 

	 	(f)	 An affirmative statement of whether any milestones with deadlines in that Contract Year under Section 2.7
and any milestones under Section 3.1(a) were met or not, the identification of the Licensed Product for which such milestone(s) were met, and the resulting Milestone Fee(s) payable; 

 

	 	(g)	 Non-Royalty Sublicensing Consideration received by Licensee segregated
on a Sublicense-by-Sublicense basis, or an affirmative statement that none was received. The report shall also itemize the permitted deductions from the Gross
Consideration received from Sublicensees used to arrive at the resulting Non-Royalty Sublicensing Consideration, segregated on a
Sublicense-by-Sublicense basis; 

  

	 	(h)	 If any consideration was received in currencies other than U.S. dollars, the report shall describe the currency
exchange calculations; and 

  

	 	(i)	 Any changes in accounting methodologies used to account for and calculate the items included in the report
since the previous report. 

  

	 	4.2	 Annual Written Progress Report and Commercialization Plan. 

Within [***] days following the end of each Contract Year until the first Sale of a Licensed Product, or upon written request by Licensor,
Licensee will deliver to Licensor a true and accurate signed written progress report that summarizes (i) Licensee’s efforts and accomplishments during the Contract Year to diligently commercialize Licensed Products, and
(ii) Licensee’s development and commercialization plans with respect to Licensed Products for the next Contract Year. The report shall also cover such activities by Affiliates and Sublicensees. The report shall contain the following
information to the extent relevant to the activities under the Agreement: 

  

					
	 Licensee: LogicBio Therapeutics, Inc.
 Licensor:
UT Southwestern Medical Center
	  	CONFIDENTIAL	  	 Exclusive License

Page 13 of 33

[***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An un-redacted version of this exhibit has
been filed separately with the commission. 

 Execution Version 

 

	 	(a)	 The name of the Licensee, the Agreement number, the names of any Affiliates and Sublicensees, and the products
being developed and/or commercialized; 

  

	 	(b)	 The progress toward completing and the plans for completing the applicable milestone events pursuant to
Sections 2.7 and 3.1(a); 

  

	 	(c)	 An affirmative statement of whether any Milestone Events with deadlines in that Contract Quarter under
Section 2.7 and any Milestone Events under Section 3.1(a) were met or not, the identification of the Licensed Product for which such Milestone Event(s) were met, and the resulting Milestone Fee(s) payable; 

 

	 	(d)	 Non-Royalty Sublicensing Consideration received by Licensee segregated
on a Sublicense-by-Sublicense basis, or an affirmative statement that none was received. The report shall also itemize the permitted deductions from the Gross
Consideration received from a Sublicensee used to arrive at the resulting Non-Royalty Sublicensing Consideration segregated on a Sublicense-by-Sublicense basis;

  

	 	(e)	 The research and development activities, including status and plans for obtaining any necessary Regulatory
Approvals, performed during the past year, and the plans for research and development activities for the next year; 

  

	 	(f)	 Beginning with the first annual report following the [***] anniversary of the Effective Date, Licensee’s
research and development efforts with respect to each Nominated Tissue; and 

  

	 	(g)	 Beginning with the first annual report following the [***] anniversary of the Effective Date, Licensee’s
research and development efforts with respect to each Active Indication. 

  

	5.	 Payment, Records, and Audits 

 

	 	5.1	 Payments. 

All amounts referred to in the Agreement are expressed in U.S. dollars without deductions for taxes, assessments, fees, or charges of any kind.
Each payment will reference the agreement number set forth at the beginning of the Agreement. All payments to Licensor will be made in U.S. dollars by check or wire transfer (Licensee to pay all wire transfer fees) payable to the payee identified in
Section 18 and sent to the payment and reporting contact in Section 18 (Notices). 
  

	 	5.2	 Sales Outside the U.S. 

If any currency conversion shall be required in connection with the calculation of payments hereunder, such conversion shall be made using the
rate used by Licensee for its financial reporting purposes in accordance with Generally Accepted Accounting 

  

					
	 Licensee: LogicBio Therapeutics, Inc.
 Licensor:
UT Southwestern Medical Center
	  	CONFIDENTIAL	  	 Exclusive License

Page 14 of 33

[***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An un-redacted version of this exhibit has
been filed separately with the commission. 

 Execution Version 

 

 
Principles (or foreign equivalent) or, in the absence of such rate, using the average of the buying and selling exchange rate for conversion between the foreign currency and U.S. Dollars, for
current transactions as reported in The Wall Street Journal on the last business days of the Contract Quarter to which such payment pertains. Licensee may not make any tax withholdings from payments to Licensor, but Licensor agrees to supply
to Licensee, upon written request, appropriate evidence from appropriate U.S. governmental agencies showing that Licensor is a resident of the United States of America for purposes of the U.S. income tax laws and is tax-exempt under such income tax laws. 
  

	 	5.3	 Late Payments. 

Amounts that are not paid when due will accrue a late charge from the due date until paid, at a rate equal to [***]% per month (or the maximum
allowed by law, if less). 
  

	 	5.4	 Records. 

For a period of [***] years after the Contract Quarter to which the records pertain, Licensee agrees that it and its Affiliates and
Sublicensees will each keep complete and accurate records of their Sales, Net Sales, Milestone Fees, and Non-Royalty Sublicensing Consideration in sufficient detail to enable such payments to be determined and
audited. 
  

	 	5.5	 Auditing. 

Licensee and its Affiliates will permit Licensor or its representatives, at Licensor’s expense, to periodically examine books, ledgers,
and records during regular business hours, at Licensee’s or its Affiliate’s place of business, on at least [***] days advance notice, to the extent necessary to verify any payment or report required under the Agreement. For each
Sublicensee, Licensee shall obtain such audit rights for Licensor or itself. If Licensee obtains such audit rights for itself, it will promptly conduct an audit of the Sublicensee’s records upon Licensor’s request, and Licensee will
furnish to Licensor a copy of the findings from such audit. No more than one audit of Licensee, each Affiliate, and each Sublicensee shall be conducted under this Section 5.5 in any Contract Year. If any amounts due Licensor have been
underpaid, then Licensee shall immediately pay Licensor the amount of such underpayment plus accrued interest due in accordance with Section 5.3. If the amount of underpayment is equal to or greater than [***]% of the total amount due for the
records so examined, Licensee will pay the cost of such audit. Such audits may, at Licensor’s sole discretion, consist of a self-audit conducted by Licensee at Licensee’s expense and certified in writing by an authorized officer of
Licensee. All information examined pursuant to this Section 5.5 shall be deemed to be the Confidential Information of the Licensee. 

  

					
	 Licensee: LogicBio Therapeutics, Inc.
 Licensor:
UT Southwestern Medical Center
	  	CONFIDENTIAL	  	 Exclusive License

Page 15 of 33

[***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An un-redacted version of this exhibit has
been filed separately with the commission. 

 Execution Version 

 

	6.	 Patent Expenses and Prosecution 

 

	 	6.1	 Patent Expenses. 

Licensee shall pay, on a pro rata basis with other licensees of the Patent Rights based on the number of such other licensees, for any
documented, out-of-pocket expenses incurred by Licensor for filing, prosecuting, defending and maintaining Patent Rights and related patent searches, for so long as, and
in such countries as the Agreement remains in effect. Licensee will pay all such patent expenses within [***] days after Licensee’s receipt of an invoice. 
  

	 	6.2	 Direction of Prosecution. 

Licensor will confer with Licensee to develop a strategy for the prosecution and maintenance of Patent Rights. Licensor will request that
copies of all documents prepared by the Prosecution Counsel for submission to governmental patent offices be provided to Licensee for review and comment prior to filing, to the extent practicable under the circumstances, and Licensor will consider
comments provided by Licensee in good faith. The Parties agree that they share a common legal interest to get valid enforceable patents and that Licensee will maintain as privileged all information received pursuant to this Section 6.2. 

 

	 	6.3	 Ownership. 

All patent applications and patents will be in the name of Licensor (and any co-owner identified in
EXHIBIT A) and owned by Licensor (and such co-owner, if any). No payments due under the Agreement will be reduced as the result of co-ownership interests in the Patent
Rights by Licensee or any other party. 
  

	 	6.4	 Foreign Filings. 

If Licensee notifies Licensor prior to the filing of a patent application within the Patent Rights in a foreign country that Licensee wishes to
not pay the cost of filing such patent application in such foreign country, then upon such notice said patent application or patent shall no longer be included in the Patent Rights and Licensee shall have no further rights thereto. Licensor shall
have the right to make alternative arrangements with Licensee for upfront payment of foreign patent expenses. 
  

	 	6.5	 Withdrawal from Paying Patent Costs. 

If at any time Licensee wishes to cease paying for any costs for a particular Patent Right or for patent prosecution in a particular
jurisdiction, Licensee must give Licensor at least 90 days prior written notice and Licensee will continue to be obligated to pay for the patent costs which reasonably accrue during said notice period. Thereafter, said patent application or patent
shall no longer be included in the Patent Rights and Licensee shall have no further rights thereto. 

  

					
	 Licensee: LogicBio Therapeutics, Inc.
 Licensor:
UT Southwestern Medical Center
	  	CONFIDENTIAL	  	 Exclusive License

Page 16 of 33

[***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An un-redacted version of this exhibit has
been filed separately with the commission. 

 Execution Version 

 

	 	6.6	 U.S. Patent and Trademark Office Entity Size Status. 

Licensee represents that as of the Effective Date the entity size status of Licensee in accordance with the regulations of the U.S. Patent and
Trademark Office is as set forth in EXHIBIT A. Licensee will inform Licensor in writing on a timely basis of any change in its U.S. Patent and Trademark Office entity size status. 

 

	7.	 Term and Termination 

 

	 	7.1	 Term. 

Unless earlier terminated as provided herein, the term of the Agreement will commence on the Effective Date and continue until the expiration
of the last-to-expire Royalty Term. 
  

	 	7.2	 Termination by Licensee. 

Licensee, at its option, may terminate the Agreement, in its entirety or with respect to any part of Licensed Subject Matter, any part of Field
or any part of Territory, by providing Licensor written notice of intent to terminate, which termination will be effective 30 days following receipt of such notice by Licensor. 

 

	 	7.3	 Termination by Licensor. 

Licensor, at its option, may immediately terminate the Agreement, in its entirety or with respect to any part of Licensed Subject Matter, any
part of Field or any part of Territory, or the exclusive nature of the license grant, upon delivery of written notice to Licensee of Licensor’s decision to terminate, if any of the following occur: 

 

	 	(a)	 Licensee becomes in arrears in any payments due under the Agreement, and Licensee fails to make the required
payment within [***] days after delivery of written notice from Licensor; or 

  

	 	(b)	 Licensee is in material breach of any non-payment provision of the
Agreement, and does not cure such material breach within [***] days after delivery of written notice from Licensor, provided that, if such breach is not reasonably capable of cure within such [***] day period, Licensee may submit, within [***] days
of such notice, a reasonable cure plan to remedy such breach as soon as possible, and, upon such submission, the [***] day cure period shall be automatically extended for so long as Licensee continues to use diligent efforts to cure such breach in
accordance with the cure plan, but for no more than [***] additional days; or 

  

	 	(c)	 Licensee breaches any payment obligation under this Agreement [***] or more times in any 12-month period, and Licensor notifies Licensee of each such breach promptly after becoming aware of each such breach, even in the event that Licensee cures such breaches in the allowed period; or

  

					
	 Licensee: LogicBio Therapeutics, Inc.
 Licensor:
UT Southwestern Medical Center
	  	CONFIDENTIAL	  	 Exclusive License

Page 17 of 33

[***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An un-redacted version of this exhibit has
been filed separately with the commission. 

 Execution Version 

 

	 	(d)	 Licensee or its Affiliate or Sublicensee initiates any proceeding or action to challenge the validity,
enforceability, or scope of one or more of the Patent Rights, or assist a third party in pursuing such a proceeding or action; provided, however, that the foregoing right of termination shall not apply if such proceeding or action to challenge the
Patent Rights is (i) made in defense of a patent infringement or breach claim first brought by the Licensor against Licensee; (ii) in response to a subpoena or as otherwise compelled by applicable law; or (iii) brought by a
Sublicensee of Licensee and Licensee has terminated all contractual relationships with such Sublicensee, including but not limited to the applicable Sublicense Agreement, following notice thereof. 

Notwithstanding the foregoing, in the event that Licensee disputes any breach under Section 7.3(a) or Section 7.3(b) during the
applicable cure period, then the cure period shall be tolled pending resolution of such dispute in accordance with the terms of this Agreement. 
  

	 	7.4	 Other Conditions of Termination. 

The Agreement will terminate: 
  

	 	(a)	 Immediately without the necessity of any action being taken by Licensor or Licensee, (i) if Licensee
becomes bankrupt or insolvent, or (ii) Licensee’s board of directors elects to liquidate its assets or dissolve its business, or (iii) Licensee ceases its business operations, or (iv) Licensee makes an assignment for the benefit
of creditors or (v) if the business or assets of Licensee are otherwise placed in the hands of a receiver, assignee or trustee, whether by voluntary act of Licensee or otherwise; or 

 

	 	(b)	 At any time by mutual written agreement between Licensee and Licensor. 

 

	 	7.5	 Effect of Termination. 

If the Agreement is terminated for any reason: 
  

	 	(a)	 All rights and licenses of Sublicensees shall terminate upon termination of the Agreement; provided however, if
a Sublicensee is (i) not an Affiliate of Licensee, (ii) in good standing and (iii) agrees in writing to assume all of the obligations of Licensee and provides Licensor with written notice thereof within [***] days after termination of
the Agreement, then such termination of this Agreement shall be without prejudice to the rights of such Sublicensee and Licensor shall enter into a license agreement directly with such Sublicensee (the “New License Agreement”) on
substantially the same terms and conditions as those set forth in this Agreement; provided, however, that (a) the New License Agreement shall provide that, subject to the statutory duties of the Attorney General of the State of Texas, in no
event shall such Sublicensee be liable to Licensor for any liabilities that may result from any legal action pursued by Licensor against Licensee for any actual or alleged default by Licensee of this Agreement, (b) the

  

					
	 Licensee: LogicBio Therapeutics, Inc.
 Licensor:
UT Southwestern Medical Center
	  	CONFIDENTIAL	  	 Exclusive License

Page 18 of 33

[***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An un-redacted version of this exhibit has
been filed separately with the commission. 

 Execution Version 

 

	 	
scope and territory of the license grant under the New License Agreement shall be no less than that granted by Licensee to such Sublicensee pursuant to the Sublicense Agreement between Licensee
and such Sublicensee, (c) the financial terms of any New License Agreement shall be such that Licensor shall receive the same consideration that it would have received under this Agreement had it not been terminated, and (d) Licensor shall
not have any obligations under the New License Agreement that are greater than or inconsistent with the obligations of Licensor under this Agreement. Each such Sublicensee shall be deemed a third party beneficiary of this Section 7.5(a).

  

	 	(b)	 Licensee shall cease making, having made, distributing, having distributed, using, selling, offering to sell,
leasing, loaning and importing any Licensed Products by the effective date of termination; and 

  

	 	(c)	 Licensee shall tender payment of all accrued royalties and other payments due to Licensor as of the effective
date of termination; and 

  

	 	(d)	 Nothing in the Agreement will be construed to release either Party from any obligation that matured prior to
the effective date of termination; and 

  

	 	(e)	 The provisions of Sections 8 (Confidentiality), 9 (Infringement and Litigation), 11 (Representations and
Disclaimers), 12 (Limit of Liability), 13 (Indemnification), 14 (Insurance), 17 (Use of Name), 18 (Notices), and 19 (General Provisions) will survive any termination or expiration of the Agreement. In addition, the provisions of Sections 3
(Compensation), 4.1 (Annual Payment and Milestone Reports), 5 (Payment, Records and Audits), and 6.1 (Patent Expenses) shall survive with respect to all activities and payment obligations accruing prior to the termination or expiration of the
Agreement. 

  

	8.	 Confidentiality 

 

	 	8.1	 Definition. 

“Confidential Information” means all information that is of a confidential and proprietary nature to Licensor or Licensee and
provided by one Party to the other Party under the Agreement, provided that (i) any information disclosed in tangible form (e.g., documents or drawings) must be clearly labeled as “confidential” or “proprietary” and
(ii) any information disclosed orally, visually or in other non-tangible form must be identified as confidential or proprietary when disclosed. Notwithstanding anything to the contrary, Licensee’s
Confidential Information shall include, without limitation, any reports or information prepared by Licensee and provided to Licensor under Section 4, and any copies of Sublicense Agreements or information extracted therefrom provided by
Licensee to Licensor. 

  

					
	 Licensee: LogicBio Therapeutics, Inc.
 Licensor:
UT Southwestern Medical Center
	  	CONFIDENTIAL	  	 Exclusive License

Page 19 of 33

[***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An un-redacted version of this exhibit has
been filed separately with the commission. 

 Execution Version 

 

	 	8.2	 Protection and Marking. 

Licensor and Licensee each agree that all Confidential Information disclosed in tangible form, and marked “confidential” and
forwarded to one by the other, or if disclosed orally, is designated as confidential at the time of disclosure: (i) is to be held in strict confidence by the receiving Party, (ii) is to be used by and under authority of the receiving Party
only as authorized in the Agreement, and (iii) shall not be disclosed by the receiving Party, its agents or employees without the prior written consent of the disclosing Party or as authorized in the Agreement. Licensee has the right to use and
disclose Confidential Information of Licensor reasonably in connection with the exercise of its rights under the Agreement, including without limitation disclosing to its employees, officers, agents, Affiliates, Sublicensees, advisors, potential
investors, acquirers, and others on a need to know basis, if such Confidential Information is provided under conditions which reasonably protect the confidentiality thereof. Each Party’s obligation of confidence hereunder includes, without
limitation, using at least the same degree of care with the disclosing Party’s Confidential Information as it uses to protect its own Confidential Information, but always at least a reasonable degree of care. 

 

	 	8.3	 Confidentiality of Terms of Agreement. 

Each Party agrees not to disclose to any third party the terms of the Agreement without the prior written consent of the other Party hereto,
except each Party may disclose the terms of the Agreement: (a) to its employees, officers, agents, Affiliates, advisors, actual or potential Sublicensees, acquirers or investors, and others on a need to know basis, in each case, under
appropriate confidentiality obligations substantially similar to those of this Section 8; and (b) to the extent necessary to comply with applicable laws and court orders (including, without limitation, The Texas Public Information Act, as
may be amended from time to time, other open records laws, decisions and rulings, and securities laws, regulations and guidance). If the Agreement is not for all fields of use, then Licensor may disclose the Field to other potential third party
licensees. Notwithstanding the foregoing, the existence of the Agreement shall not be considered Confidential Information. 
  

	 	8.4	 Disclosure Required by Court Order or Law. 

If the receiving Party is required to disclose Confidential Information of another Party hereto, or any terms of the Agreement, pursuant to the
order or requirement of a court, administrative agency, or other governmental body or applicable law, the receiving Party may disclose such Confidential Information or terms to the extent required, provided that the receiving Party shall use
reasonable efforts to provide the disclosing Party with reasonable advance notice thereof to enable the disclosing Party to seek a protective order and otherwise seek to prevent such disclosure. To the extent that Confidential Information so
disclosed does not become part of the public domain by virtue of such disclosure, it shall remain Confidential Information protected pursuant to this Section 8. 

  

					
	 Licensee: LogicBio Therapeutics, Inc.
 Licensor:
UT Southwestern Medical Center
	  	CONFIDENTIAL	  	 Exclusive License

Page 20 of 33

[***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An un-redacted version of this exhibit has
been filed separately with the commission. 

 Execution Version 

 

	 	8.5	 Copies; Return or Destruction. 

Each Party agrees not to copy or record any of the Confidential Information of the other Party, except as reasonably necessary to exercise its
rights or perform its obligations under the Agreement, and for archival and legal purposes. Promptly after expiration or termination of this Agreement, the receiving Party of any Confidential Information shall return to the disclosing Party or
destroy, at the disclosing Party’s election, all such Confidential Information that is in a tangible form which is in the possession or control of the receiving Party. One copy of Confidential Information may be retained for archival purposes
only. 
  

	 	8.6	 Continuing Obligations. 

Subject to the exclusions listed in Section 8.7, the Parties’ confidentiality obligations under the Agreement will survive
termination of the Agreement and will continue for a period of five years thereafter. 
  

	 	8.7	 Exclusions. 

Information shall not be considered Confidential Information of a disclosing Party under the Agreement to the extent that the receiving Party
can establish by competent written proof that such information: 
  

	 	(a)	 Was in the public domain at the time of disclosure; 

 

	 	(b)	 Later became part of the public domain through no act or omission of the recipient Party, its employees,
agents, successors or assigns in breach of the Agreement; 

  

	 	(c)	 Was lawfully disclosed to the recipient Party by a third party having the right to disclose it not under an
obligation of confidentiality; 

  

	 	(d)	 Was already known by the recipient Party at the time of disclosure; or 

 

	 	(e)	 Was independently developed by the recipient Party without use of the disclosing Party’s Confidential
Information. 

  

	 	8.8	 Copyright Notice. 

The placement of a copyright notice on any Confidential Information will not be construed to mean that such information has been published and
will not release the other Party from its obligation of confidentiality hereunder. 

  

					
	 Licensee: LogicBio Therapeutics, Inc.
 Licensor:
UT Southwestern Medical Center
	  	CONFIDENTIAL	  	 Exclusive License

Page 21 of 33

[***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An un-redacted version of this exhibit has
been filed separately with the commission. 

 Execution Version 

 

	9.	 Infringement and Litigation 

 

	 	9.1	 Notification. 

If either Licensor’s designated office for technology commercialization or Licensee becomes aware of any infringement or potential
infringement of Patent Rights, the applicable Party shall promptly notify the other of such in writing. 
  

	 	9.2	 Licensee’s Enforcement Rights. 

Licensee shall have the first right, but not the obligation, to enforce the Patent Rights against any infringement by a third party or defend
any declaratory judgment action with respect to the validity, enforceability or scope of one or more of the Patent Rights. Licensee shall be responsible for payment of all fees and expenses associated with such enforcement incurred by
Licensee and incurred by Licensor in providing cooperation or joining as a party as provided in Section 9.4. Any monetary recovery for actual damages or punitive damages in excess of Licensee’s documented, third-party expenses in
enforcing the Patent Rights and amounts actually reimbursed by Licensee to Licensor under this Section 9.2 shall be shared by Licensee with Licensor in the same manner as Non-Royalty Sublicensing
Consideration. 
  

	 	9.3	 Licensor’s Enforcement Rights. 

If Licensee does not file suit within six months after a written request by Licensor to initiate an infringement action or to defend against a
declaratory judgment action, then Licensor shall have the right, at its sole discretion, to bring suit to enforce or defend any Patent Right licensed hereunder against the infringing activities or declaratory judgment action, after written notice to
the Licensee. If Licensor pursues such infringement action, Licensor will bear the entire cost of the litigation, and following reimbursement of any reasonable legal fees or other documented expenses incurred by the Licensee in cooperation with such
action by Licensor, such cooperation having been requested by Licensor in writing, Licensor may retain the entire amount of any recovery or settlement. 
  

	 	9.4	 Cooperation between Licensor and Licensee. 

In any infringement suit or dispute, the Parties agree to cooperate fully with each other. At the request of the Party bringing suit, the other
Party will permit reasonable access after reasonable advance notice to all relevant personnel, records, papers, information, samples, specimens, etc., during regular business hours. 

If it is necessary to name Licensor as a party in such action, then Licensee must first obtain Licensor’s prior written permission, which
permission shall not be unreasonably withheld or delayed, provided that Licensor shall have reasonable prior input on choice of counsel on any matter where such counsel represents Licensor, and Licensee and such counsel agree to follow all required
procedures of the Texas Attorney General regarding retention of outside counsel for state entities. 

  

					
	 Licensee: LogicBio Therapeutics, Inc.
 Licensor:
UT Southwestern Medical Center
	  	CONFIDENTIAL	  	 Exclusive License

Page 22 of 33

[***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An un-redacted version of this exhibit has
been filed separately with the commission. 

 Execution Version 

 

	10.	 Export Compliance 

Licensee understands that the Arms Export Control Act (AECA), including its implementing International Traffic In Arms Regulations (ITAR), and
the Export Administration Act (EAA), including its Export Administration Regulations (EAR), are some (but not all) of the laws and regulations that comprise the U.S. export laws and regulations. Licensee further understands that the U.S. export laws
and regulations include (but are not limited to): (a) ITAR and EAR product/service/data-specific requirements; (b) ITAR and EAR ultimate destination-specific requirements; (c) ITAR and EAR end user-specific requirements;
(d) Foreign Corrupt Practices Act; and (e) anti-boycott laws and regulations. Licensee will comply with all then-current applicable export laws and regulations of the U.S. Government (and other applicable U.S. laws and regulations)
pertaining to the Licensed Products (including any associated products, items, articles, computer software, media, services, technical data, and other information). Licensee certifies that it will not, directly or indirectly, export (including any
deemed export), nor re-export (including any deemed re-export) the Licensed Products (including any associated products, items, articles, computer software, media,
services, technical data, and other information) in violation of applicable U.S. laws and regulations. Licensee will include a provision in its agreements, substantially similar to this Section 10, with its Sublicensees, third party wholesalers
and distributors, and physicians, hospitals or other healthcare providers who purchase a Licensed Product, requiring that these parties comply with all then-current applicable U.S. export laws and regulations and other applicable U.S. laws and
regulations. 
  

	11.	 Representations and Disclaimers 

 

	 	11.1	 Licensor Representations. 

Except for the rights, if any, of the Government as set forth in Section 11.2, Licensor represents and warrants to Licensee that to the
knowledge of the Licensor’s designated office for technology commercialization: 
  

	 	(i)	 Licensor is the owner or agent of the entire right, title, and interest in and to Patent Rights (other than the
right, title and interest of any joint owner identified in EXHIBIT A); 

  

	 	(ii)	 Licensor has the right to grant licenses hereunder; and 

 

	 	(iii)	 Licensor has not knowingly granted and will not knowingly grant licenses or other rights under the Patent
Rights that are in conflict with the terms and conditions in the Agreement; 

  

	 	11.2	 Government Rights. 

Licensee understands that Licensed Subject Matter may have been developed under a funding agreement with Government and, if so, that Government
may have certain rights relative thereto. The Agreement is made subject to the Government’s rights 

  

					
	 Licensee: LogicBio Therapeutics, Inc.
 Licensor:
UT Southwestern Medical Center
	  	CONFIDENTIAL	  	 Exclusive License

Page 23 of 33

[***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An un-redacted version of this exhibit has
been filed separately with the commission. 

 Execution Version 

 

 
under any such agreement and under any applicable Government law or regulation. To the extent that there is a conflict between any such agreement, such applicable law or regulation and the
Agreement, the terms of such Government agreement, and applicable law or regulation, shall prevail. Licensee agrees that, to the extent required by U.S. laws and regulations, Licensed Products used or Sold in the U.S. will be manufactured
substantially in the U.S., unless a written waiver is obtained in advance from the U.S. Government. 
  

	 	11.3	 Licensor Disclaimers. 

EXCEPT AS SPECIFICALLY SET FORTH IN SECTION 11.1, LICENSEE UNDERSTANDS AND AGREES THAT LICENSOR MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY
KIND, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, AS TO THE LICENSED PRODUCTS, OR AS TO THE OPERABILITY OR FITNESS FOR ANY USE OR PARTICULAR PURPOSE, MERCHANTABILITY, SAFETY, EFFICACY, APPROVABILITY BY REGULATORY AUTHORITIES, TIME AND COST OF
DEVELOPMENT, PATENTABILITY, AND/OR BREADTH OF PATENT RIGHTS. LICENSOR MAKES NO REPRESENTATION AS TO WHETHER ANY PATENT WITHIN PATENT RIGHTS IS VALID, OR AS TO WHETHER THERE ARE ANY PATENTS NOW HELD, OR WHICH WILL BE HELD, BY OTHERS OR BY LICENSOR
THAT MIGHT BE REQUIRED FOR USE OF PATENT RIGHTS IN FIELD. NOTHING IN THE AGREEMENT WILL BE CONSTRUED AS CONFERRING BY IMPLICATION, ESTOPPEL OR OTHERWISE ANY LICENSE OR RIGHTS TO ANY PATENTS OR TECHNOLOGY OF LICENSOR OTHER THAN THE PATENT RIGHTS,
WHETHER SUCH PATENTS ARE DOMINANT OR SUBORDINATE TO THE PATENT RIGHTS, OR THE TECHNOLOGY RIGHTS SPECIFICALLY DESCRIBED HEREIN. 
  

	 	11.4	 Licensee Representations. 

By execution of the Agreement, Licensee represents and acknowledges: 
  

	 	(i)	 that Licensee has not been induced in any way by Licensor or its employees to enter into the Agreement;

  

	 	(ii)	 that Licensee has been given an opportunity to conduct sufficient due diligence with respect to all items and
issues pertaining to this Section 11 (Representations and Disclaimers) and all other matters pertaining to the Agreement; 

  

	 	(iii)	 that Licensee has adequate knowledge and expertise, or has utilized knowledgeable and expert consultants, to
adequately conduct the due diligence; and 

  

	 	(iv)	 that Licensee accepts all risks inherent herein. 

Licensee represents that it is a duly organized, validly existing entity of the form indicated in the preamble to the Agreement, and is in good
standing under the laws of its jurisdiction of organization as indicated in the preamble of the Agreement, and has all necessary corporate or other appropriate power and authority to execute, deliver and perform its obligations hereunder. 

  

					
	 Licensee: LogicBio Therapeutics, Inc.
 Licensor:
UT Southwestern Medical Center
	  	CONFIDENTIAL	  	 Exclusive License

Page 24 of 33

[***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An un-redacted version of this exhibit has
been filed separately with the commission. 

 Execution Version 

 

	12.	 Limit of Liability 

IN NO EVENT SHALL LICENSOR, THE UNIVERSITY SYSTEM IT GOVERNS, ITS MEMBER INSTITUTIONS, INVENTORS, REGENTS, OFFICERS, EMPLOYEES, STUDENTS,
AGENTS OR AFFILIATED ENTERPRISES, BE LIABLE FOR ANY INDIRECT, SPECIAL, CONSEQUENTIAL, INCIDENTAL, EXEMPLARY, OR PUNITIVE DAMAGES (INCLUDING, WITHOUT LIMITATION, DAMAGES FOR LOSS OF PROFITS OR REVENUE) ARISING OUT OF OR IN CONNECTION WITH THE
AGREEMENT OR ITS SUBJECT MATTER, REGARDLESS OF WHETHER ANY SUCH PARTY KNOWS OR SHOULD KNOW OF THE POSSIBILITY OF SUCH DAMAGES. OTHER THAN FOR CLAIMS AGAINST LICENSEE FOR INDEMNIFICATION (SECTION 13) OR FOR MISUSE OR MISAPPROPRIATION OR INFRINGEMENT
OF LICENSOR’S INTELLECTUAL PROPERTY RIGHTS, LICENSEE WILL NOT BE LIABLE TO LICENSOR FOR ANY INDIRECT, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES (INCLUDING, WITHOUT LIMITATION, DAMAGES FOR LOSS OF PROFITS OR REVENUE) ARISING OUT OF OR IN
CONNECTION WITH THE AGREEMENT OR ITS SUBJECT MATTER, REGARDLESS OF WHETHER LICENSEE KNOWS OR SHOULD HAVE KNOWN OF THE POSSIBILITY OF SUCH DAMAGES. 
  

	13.	 Indemnification 

 

	 	13.1	 Indemnification Obligation 

Subject to Section 13.2, Licensee agrees to hold harmless, defend and indemnify Licensor, the university system it governs, its member
institutions, its Regents, officers, employees, students and agents (“Indemnified Parties”) from and against any liabilities, damages, causes of action, suits, judgments, liens, penalties, fines, losses, costs, and expenses (including,
without limitation, reasonable attorneys’ fees and other expenses of litigation) (collectively “Liabilities”) resulting from claims or demands brought by third parties against an Indemnified Party on account of any injury or death of
persons, damage to property, or any other damage or loss arising out of or in connection with the Agreement or the exercise or practice by or under authority of Licensee, its Affiliates or their Sublicensees, or third party wholesalers or
distributors, or physicians, hospitals or other healthcare providers who purchase a Licensed Product, of the rights granted hereunder. 
  

	 	13.2	 Conditions of Indemnification 

Licensee shall have no responsibility or obligation under Section 13.1 for any Liabilities to the extent caused by the gross negligence or
willful misconduct by Licensor. Licensor shall promptly inform the Licensee in writing, in reasonable detail, of any claim or threatened claim that may give rise to an obligation of indemnification under this Agreement upon the Licensor’s
designated office for technology commercialization becoming aware of such claim or threatened claim; provided, however, that the failure to give such notice shall not relieve Licensee of its indemnity obligation hereunder except to the extent that
such failure materially prejudices its rights hereunder. 

  

					
	 Licensee: LogicBio Therapeutics, Inc.
 Licensor:
UT Southwestern Medical Center
	  	CONFIDENTIAL	  	 Exclusive License

Page 25 of 33

[***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An un-redacted version of this exhibit has
been filed separately with the commission. 

 Execution Version 

 

 
Obligations to indemnify and hold harmless under Section 13.1 are subject to: (a) to the extent authorized by the Texas Constitution and the laws of the State of Texas and subject to
the statutory duties of the Texas Attorney General, the Indemnified Party giving Licensee control of the defense and settlement of the claim and demand; and (b) to the extent authorized by the Texas Constitution and the laws of the State of
Texas and subject to statutory duties of the Texas Attorney General, the Indemnified Party providing the assistance reasonably requested by Licensee, at Licensee’s expense. The indemnification obligation under Section 13.1 shall not apply
if an Indemnified Party makes any admission regarding such claim without the prior written consent of Licensee, which consent shall not be unreasonably withheld. 
  

	14.	 Insurance 

  

	 	14.1	 Insurance Requirements 

Prior to any Licensed Product being used or Sold (including for the purpose of obtaining Regulatory Approval) by Licensee, an Affiliate or a
Sublicensee, and for a period of one year after this Agreement expires or is terminated, Licensee shall, at its sole cost and expense, procure and maintain commercial general liability insurance in commercially reasonable and appropriate amounts for
the Licensed Product being used or Sold. Licensee shall use commercially reasonable efforts to have Licensor, the university system it governs, its member institutions, Regents, officers, employees, and Inventors named as additional insureds. Such
commercial general liability insurance shall provide, without limitation: (i) product liability coverage; (ii) broad form contractual liability coverage for Licensee’s indemnification under the Agreement; and (iii) coverage for
litigation costs. 
  

	 	14.2	 Evidence of Insurance and Notice of Changes 

Upon request by Licensor, Licensee shall provide Licensor with written evidence of such insurance. Additionally, Licensee shall provide
Licensor with written notice of at least [***] days prior to Licensee cancelling, not renewing, or materially changing such insurance. 
  

	15.	 Assignment 

The Agreement may not be assigned by Licensee without the prior written consent of Licensor, which consent will not be unreasonably withheld. A
merger or other transaction in which the equity holders of Licensee prior to such event hold less than a majority of the equity of the surviving or acquiring entity shall be considered an assignment of the Agreement. Notwithstanding the foregoing,
Licensee may assign this Agreement to an Affiliate of Licensee, if such assignment is for bona fide business purposes, or in connection with a merger, acquisition, change of control or sale of all or substantially all of its stock or assets to which
this Agreement relates without any such written consent being required. For any permitted assignment to be effective, (a) the Licensee must be in good standing under the Agreement, (b) the Licensee must pay Licensor the assignment fee
pursuant to Section 3.1(d), and (c) the assignee must assume in writing (a copy of which shall be promptly provided to Licensor) all of the Licensee’s interests, 

  

					
	 Licensee: LogicBio Therapeutics, Inc.
 Licensor:
UT Southwestern Medical Center
	  	CONFIDENTIAL	  	 Exclusive License

Page 26 of 33

[***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An un-redacted version of this exhibit has
been filed separately with the commission. 

 Execution Version 

 

 
rights, duties and obligations under the Agreement and agree to comply with all terms and conditions of the Agreement as if assignee were an original Party to the Agreement. The Parties
acknowledge and agree that Licensor does not have the right or authority to assign this Agreement to any other person or entity without permission from Licensee. 
  

	16.	 Governmental Markings and Approvals 

 

	 	16.1	 Patent Markings 

Licensee agrees that all Licensed Products Sold by Licensee, Affiliates, or Sublicensees will be legibly marked with the number of any
applicable patent(s) licensed hereunder as part of the Patent Rights in accordance with each country’s patent marking laws, including Title 35, U.S. Code, or if such marking is not practicable, shall so mark the accompanying outer box or
product insert for Licensed Products accordingly. 
  

	 	16.2	 Governmental Approvals and Marketing of Licensed Products 

Licensee will be responsible for obtaining all necessary governmental approvals for the development, production, distribution, Sale, and use of
any Licensed Product, at Licensee’s expense, including, without limitation, any safety studies. Licensee will have sole responsibility for any warning labels, packaging and instructions as to the use and the quality control for any Licensed
Product. 
  

	 	16.3	 Foreign Registration and Laws 

Licensee agrees to register the Agreement with any foreign governmental agency that requires such registration and Licensee will pay all costs
and legal fees in connection with such registration. Licensee is responsible for compliance with all foreign laws affecting the Agreement or the Sale of Licensed Products to the extent there is no conflict with United States law, in which case
United States law will control. 
  

	17.	 Use of Name 

Licensee will not use the name, trademarks or other marks of Licensor (or the name of the university system it governs, its member
institutions, any of its Regents or employees) without the advance written consent of Licensor. Licensor may use Licensee’s name and logo for annual reports, brochures, website and internal reports without prior consent. 

 

	18.	 Notices 

Any notice or other communication of the Parties required or permitted to be given or made under the Agreement will be in writing and will be
deemed effective when sent in a manner that provides confirmation or acknowledgement of delivery and received at the address set forth below (or as changed by written notice pursuant to this Section 18). 

  

					
	 Licensee: LogicBio Therapeutics, Inc.
 Licensor:
UT Southwestern Medical Center
	  	CONFIDENTIAL	  	 Exclusive License

Page 27 of 33

[***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An un-redacted version of this exhibit has
been filed separately with the commission. 

 Execution Version 

 

			
	 Licensee Contacts
	  	 Licensor Contacts

	Contact for Notice:	  	Contact for Notice:
	 Attn: Tom Wilton

700 Main Street

Cambridge, MA 02139

Fax: 857 242 3122

Phone: 215 316 9239

E-mail: twilton@logicbio.com
	  	 UT Southwestern Medical Center

Office for Technology Development
 Attn: Director for Technology
Commercialization
 5323 Harry Hines Boulevard, Dallas, Texas

75390-9094
 Fax: 214-951-0935
 Phone:
214-648-1888
 E-mail:
TechnologyDevelopment@UTSouthwestern.edu
  

Payment and reporting contact:

Checks in U.S. dollars payable to “UT SOUTHWESTERN”
referencing L2549-LogicBio and mailed to:

UT Southwestern Medical Center
 Lock Box 845477

Dallas, Texas 75284-5477
  

Patent prosecution contact:

Attn: Director for Technology Commercialization

Office for Technology Development
 5323 Harry Hines Boulevard,
Dallas, Texas
 75390-9094
 Fax:
214-951-0935
 Phone: 214-648-1888
 E-mail:
TechnologyDevelopment@UTSouthwestern.edu

	 Accounting contact:

	 Attn: Matthias Jaffe

700 Main Street

Cambridge, MA 02139

Fax: 857 242 3122

Phone: 617 959 7425

E-mail: mjaffe@logicbio.com

	 Patent prosecution contact:

	 Attn: Brenda Jarrell

Choate, Hall & Stewart

2 International Place

Boston, MA 02110

Phone: 617 248 5175

E-mail: bjarrell@choate.com

 Notices required under the Agreement may be delivered via E-mail
provided such notice is confirmed in writing as indicated. Notices shall be provided to each Party as specified in the “Contact for Notice” address. Each Party shall update the other Party in writing with any changes in such contact
information. 
  

	19.	 General Provisions 

 

	 	19.1	 Binding Effect. 

The Agreement is binding upon and inures to the benefit of the Parties hereto, their respective executors, administrators, heirs, permitted
assigns, and permitted successors in interest. 
  

	 	19.2	 Construction of Agreement; Interpretation. 

Headings are included for convenience only and will not be used to construe the Agreement. The Parties acknowledge and agree that both Parties
substantially 

  

					
	 Licensee: LogicBio Therapeutics, Inc.
 Licensor:
UT Southwestern Medical Center
	  	CONFIDENTIAL	  	 Exclusive License

Page 28 of 33

[***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An un-redacted version of this exhibit has
been filed separately with the commission. 

 Execution Version 

 

 
participated in negotiating the provisions of the Agreement; therefore, both Parties agree that any ambiguity in the Agreement shall not be construed more favorably toward one Party than the
other Party, regardless of which Party primarily drafted the Agreement. 
 Except where the context expressly requires otherwise:
(a) the use of any gender herein will be deemed to encompass references to either or both genders, and the use of the singular will be deemed to include the plural (and vice versa); (b) the words “include”, “includes” and
“including” will be deemed to be followed by the phrase “without limitation” and will not be interpreted to limit the provisions to which it relates; (c) the word “will” will be construed to have the same meaning
and effect as the word “shall”; (d) any definition of, or reference to, any agreement, instrument or other document herein will be construed as referring to such agreement, instrument or other document as from time to time amended,
supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein); and (e) any reference herein to any person or entity will be construed to include the person’s or
entity’s successor and assigns. 
  

	 	19.3	 Counterparts and Signatures. 

The Agreement may be executed in multiple counterparts, each of which shall be deemed an original, but all of which taken together shall
constitute one and the same instrument. A Party may evidence its execution and delivery of the Agreement by transmission of a signed copy of the Agreement via facsimile or email. In such event, the Party shall promptly provide the original signature
page(s) to the other Party. 
  

	 	19.4	 Compliance with Laws. 

Licensee will comply with all applicable federal, state and local laws and regulations, including, without limitation, all export laws and
regulations. 
  

	 	19.5	 Governing Law. 

The Agreement will be construed and enforced in accordance with laws of the U.S. and the State of Texas, without regard to choice of law and
conflicts of law principles. 
  

	 	19.6	 Modification. 

Any modification of the Agreement will be effective only if it is in writing and signed by duly authorized representatives of both Parties. No
modification will be made by email communications. 
  

	 	19.7	 Severability. 

If any provision hereof is held to be invalid, illegal or unenforceable in any jurisdiction, the Parties hereto shall negotiate in good faith a
valid, legal and enforceable substitute provision that most nearly reflects the original intent of the Parties, and all other 

  

					
	 Licensee: LogicBio Therapeutics, Inc.
 Licensor:
UT Southwestern Medical Center
	  	CONFIDENTIAL	  	 Exclusive License

Page 29 of 33

[***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An un-redacted version of this exhibit has
been filed separately with the commission. 

 Execution Version 

 

 
provisions hereof shall remain in full force and effect in such jurisdiction and shall be construed in order to carry out the intentions of the Parties hereto as nearly as may be possible. Such
invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of such other provisions in any other jurisdiction, so long as the essential essence of the Agreement remains enforceable. 

 

	 	19.8	 Third Party Beneficiaries. 

Nothing in the Agreement, express or implied, is intended to confer any benefits, rights or remedies on any entity, other than the Parties and
their permitted successors and assigns. However, if there is a joint owner of any Patent Rights identified in Exhibit A (other than Licensee), then Licensee hereby agrees that the following provisions of the Agreement extend to the benefit of the co-owner identified therein (excluding the Licensee to the extent it is a co-owner) as if such co-owner was identified in each
reference to the Licensor: the retained rights under clause (b) of Section 2.1; Section 11.3 (Licensor Disclaimers); Section 12 (Limitation of Liability); Section 13 (Indemnification); Section 14.1 (Insurance
Requirements); Section 17 (Use of Name); and Section 19.10 (Sovereign Immunity, if applicable). 
  

	 	19.9	 Waiver. 

Neither Party will be deemed to have waived any of its rights under the Agreement unless the waiver is in writing and signed by such Party. No
delay or omission of a Party in exercising or enforcing a right or remedy under the Agreement shall operate as a waiver thereof. 
  

	 	19.10	 Sovereign Immunity. 

Nothing in the Agreement shall be deemed or treated as any waiver of Licensor’s sovereign immunity. 

 

	 	19.11	 Entire Agreement. 

The Agreement constitutes the entire Agreement between the Parties regarding the subject matter hereof, and supersedes all prior written or
verbal agreements, representations and understandings relative to such matters. 
  

	 	19.12	 Claims Against Licensor for Breach of Agreement. 

Licensee acknowledges that any claim for breach of the Agreement asserted by Licensee against Licensor shall be subject to Chapter 2260 of the
Texas Government Code and that the process provided therein shall be Licensee’s sole and exclusive process for seeking a remedy for any and all alleged breaches of the Agreement by Licensor or the State of Texas. 

  

					
	 Licensee: LogicBio Therapeutics, Inc.
 Licensor:
UT Southwestern Medical Center
	  	CONFIDENTIAL	  	 Exclusive License

Page 30 of 33

[***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An un-redacted version of this exhibit has
been filed separately with the commission. 

 Execution Version 

 

	20.	 No Other Promises and Agreements; Representation by Counsel. 

Licensee expressly warrants and represents and does hereby state and represent that no promise or agreement which is not herein expressed has
been made to Licensee in executing the Agreement except those explicitly set forth herein, and that Licensee is not relying upon any statement or representation of Licensor or its representatives. Licensee is relying on Licensee’s own judgment
and has had the opportunity to be represented by legal counsel. Licensee hereby warrants and represents that Licensee understands and agrees to all terms and conditions set forth in the Agreement. 

[Signature Page Follows.] 

  

					
	 Licensee: LogicBio Therapeutics, Inc.
 Licensor:
UT Southwestern Medical Center
	  	CONFIDENTIAL	  	 Exclusive License

Page 31 of 33

[***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An un-redacted version of this exhibit has
been filed separately with the commission. 

 Execution Version 

 

	21.	 Deadline for Execution by Licensee 

If the Agreement is executed first by the Licensor and is not executed by the Licensee and received by the Licensor at the address and in the
manner set forth in Section 18 within 30 days of the date of signature set forth under the Licensor’s signature below, then the Agreement shall be null and void and of no further effect. 

IN WITNESS WHEREOF, the Parties hereto have caused their duly authorized representatives to execute this Patent License Agreement. 

 

									
	LICENSOR: Board of Regents of The University of Texas System	 		 	LICENSEE: LogicBio Therapeutics, Inc.

									
					
	By	 	/s/ Arnim Dontes	 		 	By	 	/s/ Fred Chereau

									
	Arnim Dontes	 		 	Fred Chereau
	Executive Vice President for Business Affairs	 		 	CEO
	UT Southwestern Medical Center	 		 	LogicBio Therapeutics, Inc.

									
				
		 		 	Date 	 	May 5, 2018
					
	Date 	 	5/14/2018	 		 		 	

 Approved as to Content: 
  

			
		
	By 	 	 /s/ Frank P. Grassler

			
	Frank P. Grassler, J.D.
	Vice President for Technology Development
	UT Southwestern Medical Center

 Date 5/7/18 

  

					
	 Licensee: LogicBio Therapeutics, Inc.
 Licensor:
UT Southwestern Medical Center
	  	CONFIDENTIAL	  	 Exclusive License

Page 32 of 33

[***] Portions of this exhibit have been redacted pursuant to a confidential treatment request. An un-redacted version of this exhibit has
been filed separately with the commission. 

 EXHIBIT A TO 

PATENT LICENSE AGREEMENT 

PATENT RIGHTS 
  

											
	 App. No./

Date of Filing

/Jurisdiction
	  	 Title
	  	 Inventor(s)
	  	 Jointly Owned?

(Y/N; if Y, with
whom?)
	  	 Prosecution
Counsel

	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]	  	[***]	  	[***]
	USPTO Entity Status as of Effective Date	  	Check one box:
 ☒Small

☐Large

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00288-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00288-of-00352.parquet"}]]